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Abstract 
 
Metabolic syndrome is a clinical entity that integrates a cluster of risk factors for 
cardiovascular disease and type 2 diabetes and shares common pathophysiological 
mechanisms among which stand out insulin resistance and obesity. 
The inclusion of an adipose measure in the most recent definitions of the metabolic 
syndrome was justified by the contribution of adiposity to the risk of cardiovascular 
disease and type 2 diabetes as well as to the pathophysiology of the syndrome. Adipose 
tissue may contribute to the syndrome through mechanisms related to insulin 
resistance and inflammation. Measures of abdominal obesity, that best translate 
visceral adipose tissue, may be better indicators of the risk associated with adiposity. 
Among these measures of abdominal obesity, the waist circumference has been 
highlighted, being used in the most recent definitions of the metabolic syndrome. 
Several cut-off points have been proposed for the definition of the waist circumference 
component of the metabolic syndrome. According to the most recent definition of the 
metabolic syndrome, two alternative cut-off points have been proposed for European 
populations (“European” and “Europid”). These two sets of waist circumference cut-
off points, estimated in Caucasoid population, would be the ones that best identified 
body mass index values equal to or greater than 25 kg/m2 (80 cm in women and 94 cm 
in men) and 30 kg/m2 (88 cm women and 102 cm in men). These two different cut-off 
points were also adopted by World Health Organization for the stratification of the 
metabolic risk associated with abdominal obesity (high risk and very high risk, 
respectively for lower and higher cut-off points). However, in addition to the more 
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recent recommendations on the metabolic syndrome, suggesting the use of customized 
waist circumference cut-off points for specific populations, a growing number of 
studies from different countries and ethnic groups have estimated their own cut-off 
points, that better identify the risk associated with the metabolic syndrome. In 
Portugal, the prevalence of abdominal obesity defined according to the cut-off points 
proposed by the World Health Organization is quite high, especially in women. Taking 
into account the numbers on the national prevalence of abdominal obesity, the 
suitability for the Portuguese population of the cut-off points for the waist 
circumference proposed by the most recent definition of the metabolic syndrome can 
be questioned. However, no study on the subject has yet been conducted in Portugal.  
In addition, several studies have suggested that other measures of abdominal obesity, 
such as waist-to-height ratio, may be more adequate than the waist circumference to 
estimate the risk associated with the metabolic syndrome.  
The metabolic syndrome has a high prevalence in Portugal, when compared with most 
European countries, United States of America and other regions of the globe. 
According to several cross-sectional studies, the national prevalence of the metabolic 
syndrome ranged from 24% to 28.4%, 42% to 66% and 37.2% to 69.4%, according to 
the Adult Treatment Panel III, International Diabetes Federation and Joint Interim 
Statement definitions, respectively. The high national prevalence of obesity, type 2 
diabetes and hypertension may have contributed to these numbers, along with lifestyle-
related behaviours and socio-economic characteristics. 
Several studies around the world have found differences in the prevalence of the 
metabolic syndrome among rural and urban populations. However, none of the studies 
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conducted so far in Portugal have addressed the differences between rural and urban 
populations. 
The endocrine system plays an important role in the regulation of energy balance, 
blood pressure and insulin sensitivity as well as glucose and lipid metabolism. Several 
endocrine diseases have been associated with the metabolic syndrome and the risk of 
cardiovascular disease and type 2 diabetes. Among them, hypovitaminosis D and 
thyroid dysfunction and autoimmunity stand out for their timeliness and prevalence. 
In Portugal, with the exception of studies on the prevalence of hypovitaminosis D 
carried out in specific groups, hypovitaminosis D and thyroid dysfunction and 
autoimmunity have been poorly studied, particularly in relation to cardiovascular and 
type 2 diabetes risk. 
The main objective of this thesis was to study the metabolic syndrome and its 
determinants in Portugal with a special focus on the influence of obesity and frequent 
endocrine pathologies, including hypovitaminosis D and thyroid dysfunction and 
autoimmunity. To achieve this objective, a number of specific tasks have been set. 
Firstly, the adiposity measures that best estimated the risk associated with the 
metabolic syndrome, as well as their respective cut-off points, were identified in a 
sample of the Portuguese adult population (Paper I). Secondly, the prevalence of the 
metabolic syndrome and its determinants was analysed in the same population, taking 
into account the cut-off points identified in the previous step and the distribution of 
the population by districts, NUTS II and urban or non-urban residence (Paper II). 
Subsequently, the prevalence of hypovitaminosis D, as well as the determinants of 
serum levels of 25-hydroxy vitamin D and parathyroid hormone, and its possible 
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associations with the metabolic syndrome and its components were analyzed in a sub-
sample of the same population. (Paper III). Finally, the prevalence of thyroid 
dysfunction and thyroid antibody positivity were analyzed in the same sub-sample and 
the associations of thyroid-stimulating hormone, thyroid hormones and thyroid 
antibodies with the metabolic syndrome and its components were studied (Paper IV). 
To achieve our objectives, a sample of adults enrolled in primary health care centers 
(PORMETS study) was used. In each of the 18 mainland Portuguese districts two 
health care centers were included, one of the capital and another representative of the 
non-urban area. In each health care center, 120 participants were randomly selected 
from the general practitioner´s patient lists. A total of 4095 participants were included 
between February 2007 and July 2009. A subsample including 500 participants, 
randomly selected from the initial PORMETS sample, in which additional analytical 
tests were performed, was used for the study of hypovitaminosis D and dysfunction 
and thyroid autoimmunity. 
According to our data, waist circumference, waist-to-height ratio and body adiposity 
index are the adiposity measures that provided the best evaluation of the adiposity 
component for the metabolic syndrome in the Portuguese population. As the waist 
circumference is commonly used in the definition of the metabolic syndrome, and as 
the differences found by comparison with other adiposity measures were not relevant, 
its replacement was not justified. The cut-off points estimated for the Portuguese 
population (89 cm in women and 94 cm in men) were very similar to “European” cut-
off points in women and “Europid” in men. The use of “European” cut-off points may 
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be more appropriate to avoid over-diagnosis in women. However, special attention 
should be given to waist circumference values greater than, or equal, to 94 cm in men. 
Our study confirmed a high prevalence of the metabolic syndrome in Portugal. 
According to the definition of the Joint Interim Statement and according to “European” 
cut-off points, the prevalence of metabolic syndrome was 43.1% (45.7% in women 
and 39.8% in men. Differences in prevalence were found by districts and by area of 
residence. The districts of Vila Real and Leiria had a higher prevalence while the 
districts of Bragança and Beja had a lower prevalence. Participants living in non-urban 
areas had a higher prevalence of metabolic syndrome than those living in urban areas. 
The differences found are difficult to explain, and it is not possible to exclude 
differences in eating patterns, which were not evaluated in our study. 
The metabolic syndrome prevalence was significantly higher in women and increased 
with age, as reported in previous national studies. Sedentary lifestyle and adiposity 
also had a positive association with the prevalence of the metabolic syndrome. In 
addition, socio-economic disadvantaged groups (retired, unemployed and domestic) 
also had a higher prevalence of the metabolic syndrome. The associations found, with 
a history of cardiovascular disease and diabetes type 2, as well as, with serum insulin 
levels and with HOMA score, reinforce the evidence on the increase of cardiovascular 
risk and the presence of insulin resistance in individuals with metabolic syndrome. 
According to our results, the prevalence of hypovitaminosis D was very high in 
Portugal (37.7% and 47.9% of participants with deficiency and insufficiency, 
respectively) compared to populations in Europe and other parts of the world.  Serum 
25-hydroxy-vitamin D levels were significantly lower in the months of lesser 
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ultraviolet exposure (December-May period). Taking into account our findings, it is 
crucial to develop national policies to increase knowledge about the importance of 
vitamin D for health as well as to define strategies for the identification and treatment 
of vitamin D deficiency in at-risk groups. Serum 25-hydroxy-vitamin levels were 
positively associated with exercise and negatively with body mass index and serum 
triglyceride levels. Serum levels of 25-hydroxyvitamin D were also negatively 
associated with metabolic syndrome even after adjustment for age and sex. However, 
the association lost significance after further adjustment for body mass index. Our 
results reinforce the evidence suggesting that the effects of vitamin D on the metabolic 
syndrome are largely mediated by adipose tissue. In addition, negative associations 
with triglyceride components and blood pressure were observed, that remained after 
further adjustment for body mass index. The association observed between parathyroid 
hormone and body mass index, waist circumference and its component of metabolic 
syndrome support the evidence suggesting its contribution to obesity pathophysiology. 
According to our results, the prevalence of thyroid dysfunction was 7.4% (4.9% and 
2.5% for hypothyroidism and hyperthyroidism, respectively), with 72.7% of 
previously undiagnosed cases. In addition, dysfunction was much more prevalent in 
women (3.5 times higher) and subclinical forms predominated (63.9%). The high 
prevalence of hyperthyroidism in our sample may be related to a marginal iodine 
deficiency in the Portuguese population.  
The prevalence of positivity for thyroid antibodies was 18.9% (11.9% and 15.1% for 
thyroid peroxidase and anti thyroglobulin antibodies respectively), with a higher 
expression in women (about 3 times higher). 
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No association of thyroid-stimulating hormone or thyroxine with the metabolic 
syndrome or its components was found. In addition, there were no associations of these 
hormones with the risk factors included in the metabolic syndrome or with the insulin 
resistance indicators. In contrast, triiodothyronine showed a positive association with 
the metabolic syndrome but not with its components. Additionaly, associations with 
serum triglyceride and insulin levels were also found.  
Regarding thyroid antibodies, negative associations were found between thyroid 
peroxidase antibodies and both the metabolic syndrome and its triglyceride 
component. Meanwhile, thyroglobulin antibodies did not show any associations.  
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Resumo 
 
A síndrome metabólica é uma entidade clínica que integra um cluster de factores de 
risco para a doença cardiovascular e diabetes tipo 2 e que partilham entre si 
mecanismos fisiopatológicos comuns entre os quais se destacam a resistência à 
insulina e a obesidade. 
A inclusão de uma medida adiposa nas definições mais recentes da síndrome 
metabólica foi justificada pelo contributo da adiposidade para o risco de doença 
cardiovascular e de diabetes tipo 2 assim como para a fisiopatologia da síndrome. O 
tecido adiposo pode contribuir para a síndrome através de mecanismos relacionados 
com a resistência à insulina e a inflamação. As medidas de obesidade abdominal que 
melhor traduzem o tecido adiposo visceral poderão ser melhores indicadores do risco 
associado a adiposidade. Entre estas medidas da obesidade abdominal o perímetro da 
cintura tem-se destacado, sendo usada nas mais recentes definições da síndrome 
metabólica. Vários pontos de corte têm vindo a ser propostos para a definição da 
componente perímetro da cintura da síndrome metabólica. De acordo com a mais 
recente definição da síndrome metabólica foram propostas duas alternativas de pontos 
de corte para as populações europeias (“European” e “Europid”). Estes dois conjuntos 
de pontos de corte do perímetro da cintura, estimados na população caucasóide, seriam 
aqueles que melhor identificavam valores do índice de massa corporal maiores ou 
iguais a 25 Kg/m2 (80 cm na mulher and 94 cm no homem) e 30 kg/m2 (88 cm na 
mulher and 102 cm no homem). Estes dois diferentes pontos de corte também foram 
adoptados pela Organização Mundial de Saúde para a estratificação do risco 
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metabólico associado à obesidade abdominal (risco elevado e risco muito elevado 
respectivamente para pontos de corte mais baixos e mais altos). Porém, para além das 
mais recentes recomendações sobre a síndrome metabólica terem sugerido o uso de 
pontos de corte do perímetro da cintura personalizados para populações específicas, 
um número crescente de estudos, com origem em diferentes países e étnias, tem vindo 
a estimar pontos de corte específicos para a identificação do risco associado à síndrome 
metabólica. Em Portugal a prevalência da obesidade abdominal, definida de acordo 
com os pontos de corte propostos pela Organização Mundial de Saúde, é bastante 
elevada, nomeadamente na mulher. Tendo em conta estes dados sobre a prevalência 
nacional da obesidade abdominal, poderá ser interrogada a adequação para a população 
portuguesa dos pontos de corte do perímetro da cintura propostos pela mais recente 
definição da síndrome metabólica. Porém, ainda não foi realizado em Portugal 
qualquer estudo sobre o assunto. Para além disso, vários estudos têm vindo a sugerir 
que outras medidas da obesidade abdominal, nomeadamente a razão cintura-altura, 
poderão ser mais adequadas do que o perímetro da cintura para a estimativa do risco 
associado à síndrome metabólica. 
A síndrome metabólica tem uma elevada prevalência em Portugal, quando comparada 
com a maior parte dos países Europeus, Estados Unidos da América e outras regiões 
do globo. De acordo com vários estudos transversais, a prevalência nacional da 
síndrome metabólica variou entre 24% e 28.4%, 42% e 66% e 37.2% e 69.4%, de 
acordo com as definições Adult Treatment Panel III, International Diabetes 
Federation e Joint Interim Statement, respectivamente. A elevada prevalência nacional 
da obesidade, da diabetes tipo 2 e da hipertensão arterial podem ter contribuído para 
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estes números, assim como os comportamentos relacionados com o estilo de vida e 
características socio-económicas. 
Vários estudos, em todo o mundo, têm encontrado diferenças da prevalência da 
síndrome metabólica entre populações rurais e urbanas. Nenhum dos estudos 
realizados até agora em Portugal abordou as diferenças entre as populações não 
urbanas e urbanas. 
O sistema endócrino tem um importante papel na regulação do equilibrio energético, 
da pressão arterial e da sensibilidade à insulina assim como no metabolismo da glicose 
e dos lípidos. Diversas doenças endócrinas têm sido associadas com a síndrome 
metabólica e o risco de doença cardiovascular e de diabetes tipo 2. Entre elas destacam-
se pela sua actualidade e prevalência a hipovitaminose D e a disfunção e 
autoimunidade tiroideias. Em Portugal, para além dos estudos sobre a prevalência da 
hipovitaminose D realizados em grupos específicos, a hipovitaminose D e a disfunção 
e a autoimunidade tiroideias têm sido pouco estudadas, nomeadamente no que se refere 
ao risco cardiovascular e de diabetes tipo 2. 
O principal objectivo desta tese, foi estudar a síndrome metabólica e as suas 
determinantes em Portugal com um foco especial na influência da obesidade e de 
patologias endócrinas frequentes, incluindo a hipovitaminose D e a disfunção e 
autoimunidade tiroideias. 
Para atingir este objectivo, foram estabelecidas várias tarefas específicas. Primeiro, 
foram identificadas as medidas adiposas que melhor estimavam o risco associado à 
síndrome metabólica numa amostra da população portuguesa adulta, assim como os 
respectivos pontos de corte (Paper I). De seguida, foi analisada a prevalência da 
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síndrome metabólica e das suas determinantes, na mesma população tendo em conta 
os pontos de corte identificados no passo anterior e a distribuição da população por 
distritos, NUTS II e residência urbana ou não urbana (Paper II). Posteriormente, foi 
analisada numa subamostra da mesma população, a prevalência da hipovitaminose D, 
assim como as determinantes dos níveis séricos da 25-hidroxi-vitamina D e da 
hormona paratiroideia e as suas possíveis associações com a síndrome metabólica e as 
suas componentes (Paper III). Por fim, na mesma subamostra, foi analisada a 
prevalência da disfunção tiroideia e da positividade dos anticorpos tiroideus e foram 
estudadas as associações da thyroid-stimulating hormone, das hormonas tiroideias e 
dos anticorpos tiroideus com a síndrome metabólica e as suas componentes (Paper IV). 
Para a concretização destes objectivos foi usada uma amostra de adultos incritos nos 
cuidados de saúde primários (estudo PORMETS). Em cada um dos 18 distritos de 
Portugal continental foram incluídos 2 centros de saúde, um da capital e outro 
representativo de área não urbana. Em cada centro de saúde 120 participantes foram 
selecionados aleatoriamente a partir da listagem dos utentes inscritos. Foram incluídos 
4095 participantes entre Fevereiro de 2007 e Julho de 2009. Uma subamostra incluindo 
500 participantes selecionada aleatoriamente a partir da amostra inicial do estudo 
PORMETS, em que foram feitos exames analíticos adicionias, foi usada para o estudo 
da hipovitaminose D e da disfunção e autoimunidade tiroideias. 
De acordo com os nossos resultados, o perímetro da cintura, a razão cintura-altura e o 
body adiposity índex são as medidas adiposas que melhor estimam a componente 
adiposa da síndrome metabólica. Como o perímetro da cintura é habitualmente usado 
na definição da síndrome metabólica e porque as diferenças encontradas por 
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comparação com as outras medidas da adiposidade foram pouco relevantes, não se 
justificou a sua substituição. Os pontos de corte do perímetro da cintura estimados para 
a população portuguesa (89 cm na mulher e 94 cm no homem) eram muito semelhantes 
aos pontos de corte “European” na mulher e “Europid” no homem. O uso dos pontos 
de corte “European” poderá ser mais apropriado para evitar o sobrediagnóstico na 
mulher. Porém, uma especial atenção deverá ser dada a valores do perímetro da cintura 
maiores ou iguais a 94 cm no homem. 
O nosso estudo confirmou uma elevada prevalência da síndrome metabólica em 
Portugal. 
De acordo com a definição da Joint Interim Statement e de acordo com pontos de corte 
“European” a prevalência da síndrome metabólica foi de 43.1% (45.7% nas mulheres 
e 39.8% nos homens). Foram encontradas diferenças na prevalência por distritos e por 
área de residência. Os distritos de Vila Real e Leiria apresentaram maior prevalência 
e os distritos de Bragança e Beja menor prevalência. Os participantes residentes em 
áreas rurais apresentaram maior prevalência do que os residentes em áreas urbanas. As 
diferenças encontradas são de difícil explicação, não se podendo excluir diferenças nos 
hábitos alimentares, que não foram avaliados no nosso estudo. 
A prevalência foi significativamente maior no sexo feminino e aumentou com idade, 
como referido em estudos nacionais anteriores. O sedentarismo e a adiposidade 
também apresentaram uma associação positiva com a prevalência da síndrome 
metabólica. Para além disso, os grupos mais desfavorecidos do ponto de vista sócio-
económico (reformados, desempregados e domésticas), também apresentaram maior 
prevalência da síndrome metabólica. As associações encontradas com os antecedentes 
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de doença cardiovasculares e de diabetes tpo 2 assim como com os níveis séricos de 
insulina e com o HOMA, reforçam a evidência sobre o aumento do risco 
cardiovascular e a presença de insulinorresistência nos indivíduos com síndrome 
metabólica. 
De acordo com os nossos resultados a prevalência de hipovitaminose D era muito 
elevada em Portugal (37.7% e 47.9% dos participantes com deficiência e insuficiência, 
respectivamente) por comparação com populações europeias e de outras partes do 
mundo.  
Os níveis de 25-hidroxi-vitamina D eram ainda significativamente mais baixos nos 
meses com menor exposição ultra-violeta (período Dezembro-Maio). Tendo em conta 
os nossos resultados torna-se crucial o desenvolvimento de políticas nacionais para 
aumentar o conhecimento sobre a importância da vitamina D para a saúde assim como 
definir estratégias para a identificação e tratamento da deficiência da vitamina D em 
grupos de risco. 
Os níveis séricos da 25-hidroxi-vitamina D apresentaram uma associação positiva com 
o exercício físico e negativa com o índice de massa corporal e os níveis séricos de 
triglicéridos. Os níveis séricos de 25-hidroxivitamina D apresentaram ainda uma 
associação negativa com a síndrome metabólica após ajustamento para idade e sexo. 
Porém a associação perdeu significância após ajustamento adicional para o índice de 
massa corporal. Estes resultados vêm reforçar a evidência que sugere que os efeitos da 
vitamina D na síndrome metabólica são mediados em grande parte pelo tecido adiposo. 
Para além disso foram observadas associações negativas com os componentes 
triglicéridos e pressão arterial da síndrome metabólica que se mantiveram após 
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ajustamento adicional para o índice de massa corporal. A associação da hormona 
paratiroideia com o índice de massa corporal e com o perímetro da cintura e respectivo 
componente da síndrome metabólica vem apoiar a evidência que sugere o seu 
contributo para a obesidade.  
De acordo com os nossos resultados a prevalência da disfunção tiroideia foi de 7.4% 
(4.9% e 2.5% para o hipotiroidismo e hipertiroidismo, respectivamente), com 72.7% 
dos casos não diagnosticados previamente. Para além disso, a disfunção foi muito mais 
prevalente nas mulheres (3.5 vezes superior) e as formas subclínicas predominaram 
(63.9%). A elevada prevalência do hipertiroidismo na nossa amostra pode estar 
relacionada com uma deficiência marginal de iodo na população portuguesa. A 
prevalência da positividade para os anticorpos tiroideus foi de 18.9% (11.9% e 15.1% 
para os anticorpos anti-peroxidase tiroideia e anti-tireoglobulina respectivamente), 
com uma maior expressão nas mulheres (cerca de 3 vezes superior).  
Não foi encontrada qualquer associação da thyroid-stimulating hormone ou da tiroxina 
com a síndome metabólica ou com as suas componentes. Para além disso, não se 
encontraram associações destas hormonas com os factores de risco incluídos na 
síndrome metabólica ou com os indicadores de insulino-resistência. Em contrapartida, 
a triiodotironina apresentou uma associação positiva com a síndrome metabólica mas 
não com as suas componentes. Para além disso, foram ainda encontradas associações 
com os níveis séricos dos triglicéridos e da insulina.  
No que respeita aos anticorpos tiroideus encontraram-se associações negativas com a 
síndrome metabólica e com sua acomponente triglicéridos para os anticorpos anti-
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peroxidase tiroideia. Os anticorpos anti-tireoglobulina não apresentaram quaisquer 
associações.  
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I. Background 
 
1. Metabolic syndrome: concept, definitions and 
controversies 
The concept of metabolic syndrome (MetS) results from the co-occurrence of 
cardiovascular disease (CVD) and type 2 diabetes risk factors.  
The MetS, from an epidemiological and clinical point of view, is since 2009 an entity 
with a clear and consensual definition and integrates five independent components 1. 
Several scientific organizations, including the World Health Organization (WHO) 2, 
the European Group for Study of Insulin Resistance (EGIR) 3, the National Heart, 
Lung, and Blood Institute (NHLBI) 1, 4-8, , the American Heart Association (AHA) 1, 4-
8, , the American Diabetes Association (ADA) 4, 5, 8, , the American Association of 
Clinical Endocrinologists (AACE) 9 , the American College of Endocrinology (ACE) 
9, the International Diabetes Federation (IDF) 1, 10, 11 , the World Heart Federation 
(WHF) 1, the International Atherosclerosis Society (IAS) 1, and the International 
Association for the Study of Obesity (IASO) 1 , proposed widely used epidemiological 
definitions of the MetS, (Tables 1, 2 and 3).  
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Table 1. Metabolic Syndrome definitions 
 WHO (1998) 2 EGIR (1999) 3 ATP III (2001) 4 
Insulin resistance IR: glucose uptake ˂ lower quartile clamp) 
IR: glucose uptake ˂ lower quartile (clamp) 
or fasting hyperinsulinaemia 
Not included 
Glucose Impaired glucose regulation * or diabetes 
Fasting plasma glucose ≥ 6.1 mmol/L (110 
mg/dL) and non diabetic 
Fasting plasma glucose ≥ 6.1 mmol/L (110 
mg/dL) or diabetes 
Triglycerides ≥ 1.7 mmol/L (150 mg/dL) 
> 2.0 mmol/L (180 mg/dL) or treatment for 
dyslipidaemia 
≥ 1.7 mmol/L (150 mg/dL) 
HDL cholesterol 
M ˂ 0.9 mmol/L (35 mg/dl) 
W ˂ 1.0 mmol/L (39 mg/dl) 
˂ 1.0 mmol/L (40 mg/dL) 
or treatment for dyslipidaemia 
M ˂  1.04 mmol/L (40 mg/dL) 
W ˂ 1.30 mmol/L (50 mg/dL) 
Blood pressure ≥ 160/90 mmHg 
≥ 140/90 mmHg 
or treatment for hypertension 
≥ 130/85 mmHg 
Abdominal obesity 
M: WHR > 0.90 
W: WHR > 0.85 
and /or BMI > 30 Kg/m2 ** 
M: WC ≥ 94 cm 
W: WC ≥ 80 cm 
M: WC > 102 cm 
W: WC > 88 cm 
Microalbuminuria UAE rate ≥ 20 µg/min or UACR ≥ 20 mg/g Not included Not included 
MetS criteria 
IR and/or glucose component and 
≥ 2 of  4 possible components: 
a. Atherogenic dyslipidemia ***; 
b. Blood pressure; 
c. Abdominal obesity; 
d. Microalbuminuria. 
IR and ≥ 2 of 4 possible components: 
a. Glucose; 
b. Dyslipidaemia ***; 
c. Blood pressure; 
d. Abdominal obesity. 
≥ 3 of 5 possible components: 
a. Glucose 
b. Triglycerides 
c. HDL cholesterol; 
d. Blood pressure; 
e. Abdominal obesity. 
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ATP III, National Cholesterol Education Program (NCEP) Adult Treatment Panel III; M, men; W, Women; IR, insulin resistance; HDL, high density cholesterol; 
WC, waist circumference; WHR, waist-to-hip ratio; BMI, body mass index; UAE, urinary albumin excretion; UACR, urinary albumin-to-creatinine ratio; MetS, 
metabolic syndrome. 
* Impaired glucose regulation includes impaired glucose tolerance (IGT) and impaired fasting glycaemia (IFG). ** 10-15% lower for non-Caucasian. *** 
Triglycerides and/or HDL cholesterol. 
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Table 2. Metabolic Syndrome definitions 
 
 
 
 AACE (2003) 9 AHA/NHLBI/ADA (2004) 8 AHA/NHLBI (2005) 6 
Glucose 
Fasting plasma glucose ≥ 110 mg/dL and  
˂ 126 mg/dL (excluding diabetes) or IGT * 
Fasting plasma glucose ≥ 100 mg/dL 
(including diabetes) 
Fasting plasma glucose ≥ 100 mg/dL 
(including diabetes) or drug treatment 
Triglycerides > 1.7 mmol/L (150 mg/dL) ≥ 1.7 mmol/L (150 mg/dL) 
≥ 1.7 mmol/L (150 mg/dL) or drug 
treatment  
HDL cholesterol 
M ˂ 40 mg/dL 
W ˂ 50 mg/dL 
M ˂ 1.04 mmol/L (40 mg/dL) 
W ˂ 1.30 mmol/L (50 mg/dL) 
M ˂ 1.03 mmol/L (40 mg/dL)  
W ˂ 1.30 mmol/L (50 mg/dL) or drug 
treatment  
Blood pressure > 130/85 mmHg ≥ 130/85 mmHg ≥ 130/85 mmHg or drug treatment  
Abdominal 
obesity 
M: WC > 102 cm  
W: WC > 88 cm  
or BMI > 25 Kg/m2 
M: WC > 102 cm  
W: WC > 88 cm 
M: WC ≥102 cm  
W: WC ≥ 88 cm  
MetS criteria 
Presence of a Risk factor for IRS ** 
and ≥ 2 of 4 possible components: 
a.  Glucose; 
b. Triglycerides; 
c. HDL cholesterol; 
d. Blood pressure. 
≥ 3 of 5 possible components: 
a. Glucose; 
b. Triglycerides; 
c. HDL cholesterol; 
d. Blood pressure; 
e. Abdominal obesity. 
≥ 3 of 5 possible components: 
a. Glucose; 
b. Triglycerides; 
c. HDL cholesterol; 
d. Blood pressure; 
e. Abdominal obesity. 
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IRS, Insulin resistance syndrome; M, men; W, women; HDL, high-density cholesterol; WC, waist circumference; BMI, body mass index; MetS, metabolic syndrome. 
* IGT: Plasma glucose 120 minutes post-glucose challenge (75 g) ≥ 140 mg/dl and ≤ 200 mg/dl. 
** Risk factors for IRS: Abdominal obesity; sedentary lifestyle; age >40 years; non-Caucasian ethnicity; family history of type 2 diabetes, hypertension or 
cardiovascular disease; history of glucose intolerance or gestational diabetes; acanthosis nigricans; polycystic ovary syndrome; non-alcoholic fatty liver disease. 
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Table 3. Metabolic Syndrome definitions 
 
JIS, Joint Interim Statement; M, men; W, women; HDL, high density cholesterol; WC, waist 
circumference; BMI, body mass index; MetS, metabolic syndrome. 
*Other Ethnic groups: South Asians, Chinese and Central Americans (Men ≥ 90 cm / Women ≥ 80 cm); 
Japanese (Men ≥ 85 cm / Women ≥ 90 cm); Saharan Africans, Eastern Mediterranean and Middle East 
(Arab) populations - use Europids criteria until more specific data are available. 
** Population- and country- specific groups: Europid/IDF (Men ≥ 94 cm / Women ≥ 80 cm); 
European/European Cardiovascular Societies (Men ≥ 102 cm / Women ≥ 88 cm); Caucasian /WHO 
(Men ≥ 94 / 102 cm/ Women ≥ 80 / 88 cm); United States/ATP III (Men ≥ 102 cm / Women ≥ 88 cm); 
Asian (including Japanese)/IDF (Men ≥ 90 cm / Women ≥ 80 cm); Asian/WHO (Men  ≥ 90 cm / Women 
≥ 80 cm); Japanese/Japanese Obesity Society (Men ≥ 85 cm / Women ≥ 90 cm); China/Cooperative 
Task Force (Men ≥ 85 cm / Women ≥ 80 cm); Middle East, Mediterranean/IDF (Men ≥ 102 cm / Women 
 IDF (2005) 10 JIS (2009) 1 
Glucose 
Fasting plasma glucose ≥ 100 mg/dL 
(5.6 mmol/L) or type 2 diabetes 
Fasting plasma glucose ≥ 100 mg/dL 
(5.6 mmol/L) or drug treatment 
Triglycerides 
≥  150 mg/dL (1.7 mmol/L) or drug 
treatment 
≥  150 mg/dl (1.7 mmol/L) or drug 
treatment 
HDL 
cholesterol 
M ˂ 40 mg/dL (1.03 mmol/L)  
W ˂ 50 mg/dl (1.29 mmol/L)  
or drug treatment 
M ˂ 40 mg/dL (1.0 mmol/L) 
W ˂ 50 mg/dl (1.3 mmol/L) 
or drug treatment 
Blood pressure ≥ 130/85 mmHg or drug treatment ≥ 130/85 mmHg or drug treatment 
Abdominal 
obesity 
Ethnicity-specific* 
Europids criteria: 
M: WC ≥ 80 cm  
W: WC ≥ 94 cm  
or BMI ≥ 30 Kg/m2 
Population- and country-specific 
definitions ** 
MetS criteria 
Abdominal obesity and  ≥ 2 of 4 
possible components: 
a.  Glucose; 
b. Triglycerides; 
c. HDL cholesterol; 
d. Blood pressure. 
≥ 3 of 5 possible components: 
a. Glucose 
b. Triglycerides 
c. HDL cholesterol; 
d. Blood pressure; 
e. Abdominal obesity. 
  
Background | 7 
 
≥ 88 cm); Sub-Saharan African/IDF (Men ≥ 94 cm / Women ≥ 80 cm); Ethnic Central and South 
American/IDF (Men ≥ 90 cm / Women ≥ 80 cm). 
 
The WHO definition of MetS 2 (Table 1) was the first with global impact. A set of 
criteria was proposed for a clinical diagnosis of the MetS, including impaired fasting 
glycaemia. 
(IFG), impaired glucose tolerance (IGT) or diabetes mellitus and/or insulin resistance 
(IR) and at least 2 of 4 other possible components: blood pressure (BP), dyslipidaemia 
[triglycerides and/or high-density lipoprotein (HDL) cholesterol], abdominal obesity 
(AO) and microalbuminuria. Although this group valued the central role of IR in the 
pathophysiology of the MetS, it was considered more appropriate to use the term 
"metabolic syndrome" instead of "syndrome X", as it was previously used 12, because, 
in the later definition, AO was not included.  
The EGIR 3 consensus criticized the term MetS proposed by the WHO and proposed 
to retain the term insulin resistance syndrome (IRS) arguing that IR was the central 
element. The IRS was thus defined by the presence of IR or fasting hyperinsulinaemia 
(the highest 25% fasting insulin concentrations of a nondiabetic population) and two 
or more other components, including hyperglycaemia, BP, dyslipidaemia 
(triglycerides or HDL cholesterol) and AO.  
The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP 
III) 4, 5 recommendations (Table 1) proposed a clinical definition of the MetS including 
5 components: waist circumference (WC), triglycerides, HDL cholesterol, BP and 
glucose; the diagnosis of the MetS was made when 3 or more of the risk components 
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were present. The ATP III panel, individualized the two components of the atherogenic 
dyslipidaemia and recognized the phenomenon of clustering of metabolic risk factors 
and the link to IR, but it was not conclusive about the pathogenic mechanisms of the 
syndrome, because the mechanisms underlying the link of IR with the CVD risk factors 
were not fully understood; as such the IR component was excluded from the definition.  
The AACE and the ACE statement 9 (Table 2), adopted the lipidic and BP criteria of 
ATP III but proposed changes to other components of the definition. According to 
them, individuals with diabetes should be excluded and changes were proposed to the 
glucose component. Postprandial glucose was included as an alternative to fasting 
glucose, due to its limitations 13, 14. Unlike the definitions of WHO, EGIR and ATP III, 
in the AACE definition, the presence of at least one of several IRS risk factors was 
mandatory for diagnosis. The following IRS risk factors were considered: AO; 
sedentary lifestyle; age >40 years; non-Caucasian ethnicity; family history of type 2 
diabetes, hypertension or CVD; history of glucose intolerance or gestational diabetes; 
acanthosis nigricans; polycystic ovary syndrome; non-alcoholic fatty liver disease. 
Like EGIR, the AACE statement preferred to use the term IRS instead of MetS, 
adopted by WHO and ATP III, to reinforce the central pathophysiological and unifying 
role of IR and compensatory hyperinsulinemia. 
In 2004 8, a report of the AHA, NHLBI and ADA Conference on Scientific Issues 
Related to Management of MetS (Table 2) was published. According to the follow-up 
report on the diagnosis of diabetes mellitus of the ADA 15 published in 2003, it was 
proposed a new cut-off point for fasting plasma glucose of 100 mg/dl, applicable to 
define the glucose component of the MetS according to ATP III definition. 
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In 2005, the AHA and NHLBI reaffirmed the utility of ATP III criteria, with minor 
modifications 6, 7 (Table 2). The new cut-off point for fasting plasma glucose (100 
mg/dL) was adopted. This statement, according to previous positions, maintained the 
term MetS rather than IRS. According to these recommendations, the AO 16 and IR 12, 
17-19 were considered as predominant underlying risk factors for MetS and AO was 
stated as the main modifiable risk factor. Compared with the AHA, NHLBI and ADA, 
2004 definition, the subjects on drug treatment for any of the components of the 
syndrome were included for diagnostic purposes. 
According to the 2005 IDF definition 10, 11 (Table 3), AO had a key role in the 
pathogenesis of MetS and, for the first time, its presence was considered mandatory 
for the diagnosis of MetS. In addition, and in a much more extensive and clear way, 
the ethnic differences regarding the cut-off points for the definition of the AO 
component were valued. MetS was defined by the AO component plus any two of four 
additional traits: dysglycaemia, raised BP, elevated triglyceride levels and low HDL 
cholesterol levels. 
Finally, in 2009, a Joint Interim Statement (JIS) definition 1 (Table 3) used the same 
components and the same methodology of the AHA and NHLBI statement of 2005 6, 
7, for diagnosis of MetS. Following the recommendations of the IDF to individualize 
WC cut-off points due to ethnic and geographic specificities, different cut-off points 
were proposed according to populations and ethnicity. With regard to the European 
Caucasian population, two different cut-off points were proposed: "Europid" 
according to IDF 10 and “European "according to the European Cardiovascular 
Societies 20. 
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2. The adiposity component: pathophysiological and cut-off 
points controversies 
The contribution of obesity to CVD 21-27 and diabetes risk 28-33 justified, as previously 
stated, the inclusion of an adiposity measure, in the most frequently used definitions 
of MetS. However, the relevance of the adipose component for the syndrome and its 
definition has been the subject of some controversy 2-4, 6, 9, 11. In fact, although obesity 
and IR play a key role in the pathophysiology of the MetS, their relative importance 
has been the subject of much debate 3, 9.  
Total body and abdominal fat are distributed principally by two compartments, the 
subcutaneous adipose tissue and the visceral adipose tissue (VAT) 34, 35, and there is 
evidence that VAT may have a stronger impact than total body fat on IR 36-43.  Total 
body fat and VAT may be estimated by several proxy anthropometric indicators, 
including body mass index (BMI) on the one hand, and WC, waist-to-hip ratio (WHR) 
and waist-to-height ratio (WHtR) 44, on the other hand. Despite its good correlation 
with total body fat, BMI is only moderately correlated with VAT 45. In addition, AO 
anthropometric measures present stronger associations with VAT than total body fat 
measures 46. Furthermore, AO anthropometric measures (WC, WHR and WHtR) have 
also shown to be better predictors of CVD risk and mortality 25, 47-55 and diabetes risk 
28-31, than BMI. Two systematic reviews and meta-analysis 56, 57 even suggested that 
WHtR was modestly superior to WC for CVD risk assessment. In addition, WHtR may 
be a better predictor of diabetes than other AO measures 58. Nevertheless, the 
differences between these several measures may not be clinically relevant 54. Another 
measure of total body adiposity, the body adiposity index (BAI), that is calculated from 
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hip circumference (HC) and height, has been proposed 59. BMI and BAI performed 
similarly when estimating the percentage of fat 46. However, BAI showed a lower 
correlation with VAT and the homeostatic model assessment (HOMA) 60, 61, and may 
not be as good as BMI in predicting CVD risk 46, 62-66, all-cause and CVD mortality 62, 
and diabetes risk 63. 
According to the WHO 2 proposal, AO (or central obesity, as it was called in the 
publication) was included as a component of the MetS, and was defined by WHR (> 
0.90 in males and >0.85 in females) and/or BMI > 30 Kg/ m2. Although the association 
of AO with IR 67, 68 and other components of the syndrome 12, 17, 69-77 had already been 
described, it was with this WHO publication that AO gained prominence as a 
fundamental part of the syndrome. In fact, AO was not included in the original 
“Syndrome X” described in 1988 by Reaven 12, 17, 18; however, it was posteriorly 
included in the “deadly quartet” of Kaplan 69 and in the “syndrome X plus” of Zimmet 
77, in 1989 and 1991, respectively.  
The EGIR definition 3, adopted and confirmed the WC as a measure of the adipose 
component of the MetS. They preferred to use the WC as an anthropometric measure 
of the abdominal adipose tissue because it was simpler to measure than WHR, and WC 
better correlated with intra-abdominal VAT accumulation than BMI or WHR 78, 79. The 
WC cut-off points (94 cm for men and 80 cm for women) were proposed based in a 
cross-sectional study (MORGEN project) 80, 81 conducted by Lean and Han in 1993-
1995, including 5887 men and 7018 women aged 20–59 years from the general 
population of Netherlands. These cut-off points, previously identified in 1992 by the 
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same investigators in a population sample of Glasgow 82, were the ones that better 
identified subjects with a BMI ≥ 25 Kg/m2.  
The NCEP ATP III 4, 5 definition also included WC cut-off points. These cut-off points 
(88 cm and 102 cm, respectively in women and men) identified subjects with a BMI≥ 
30 Kg/m2 83, 84. The choice of EGIR and ATP III cut-off points was based on the same 
publications of Lean and Han 80-82. 
In 2003, for the first time in a clear way, the AACE recommendations 9 highlighted 
the need for adjustment of anthropometric measures of adiposity to ethnicity. Cut-off 
points 10 to 15% lower were suggested for non-Caucasians. In addition, the BMI was 
recovered and was added to the WC as an anthropometric measure of adiposity 85. 
According to the AACE definition, BMI and WC could be used alternatively as 
anthropometric measurements of adiposity. The cut-off points of 25 Kg/m2 for BMI 
and of 102 cm and 88 cm for WC, respectively in men and women, were proposed.  
In 2004, the NHLBI and the AHA published a report on the MetS 86. According to this 
report, the pathogenesis of the MetS included three potential etiological categories: 
obesity and disorders of adipose tissue; IR; and a constellation of independent factors 
that mediate specific components of the MetS. Other factors, like ageing, 
proinflammatory state, and hormonal changes, were implicated as contributors as well, 
but the independent role of AO was stressed in the report. 
In 2005, the AHA and NHLBI 6, 7 reinforced ATP III recommendations by maintaining 
the same WC cut-off points. However, lower WC cut-off points were suggested for 
populations from South Asia, China, Japan, and other Asian countries 87-91. 
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Also in the same year, the IDF 10, 11 proposed new diagnostic criteria for MetS. 
According to IDF, AO, estimated by WC, played a key role in the early stages of MetS 
pathogenesis. This assumption was supported by evidence of a strong association of 
WC with IR and the various components of MetS and with the risk of CVD. The 
presence of AO was considered as a precondition for the identification of MetS and 
the proposed cut-off points could vary between countries/ethnic groups (“Europid”, 
South Asians, Chinese, Japanese, Ethnic-South and Central Americans and Sub-
Saharan Africans). In the USA population, the ATP III cut-off points were maintained. 
In the “Europid” group (white people of European origin) cut-off point of 94 cm in 
males and 80 cm in females were proposed; these cut-off points were based on cross-
sectional data from the Netherlands studies 80-82 and were the best values for 
identifying people with increased adiposity, defined as a BMI of ≥25 kg/m2 or WHR 
≥0.90 for men and ≥ 0.85 for women. The IDF also suggested the need to conduct 
longitudinal studies with risk assessment of CVD and diabetes in various ethnic groups 
to estimate the most appropriate WC cut-off points.  
Finally, in 2009, the JIS 1 proposed a harmonizing definition of the MetS, suggesting 
the use of national or regional WC cut-off points to define the adiposity component of 
MetS. Two sets of cut-off points were proposed for European individuals: “Europid” 
(94 cm in men and 80 cm in women) and “European” (102 cm in men and 88 cm in 
women), according to the IDF 10, 11 and the European Cardiovascular Societies 20, 
respectively. 
As stated before, these two sets of cut-off points, estimated in Caucasian populations, 
were those that best identified BMI values greater than or equal to 25 kg/m2 (80 cm in 
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women and 94 cm in men) and 30 kg/m2 (88 cm women and 102 cm in men) 80-82. Its 
use was reinforced by a WHO technical report on obesity that confirmed these sex-
specific WC cut-off points to identify the risk of metabolic complications associated 
with obesity in Caucasians 92. The risk was classified as increased (or high) or 
substantially increased (or very high), according to the lower and higher WC cut-off 
points respectively 93.  
An increasing number of studies, from several countries and ethnicities, reported 
different values for the cut-off points of WC and other anthropometric measures of 
AO that best estimated CVD and diabetes risk 94, 95.  
In Portugal, where the prevalence and trend of obesity has risen to “pandemic” 
proportions 96-102, following what is happening in Europe 103-105 and worldwide 106, 107, 
several studies were carried out to evaluate the prevalence 97, 99 and incidence 98 of AO.  
According to the EPIPorto study 108, a cohort study conducted in the city of Porto in 
the period of 1999-2003, the prevalence of AO (˃ 88 cm in women and > 102 cm in 
men) was 40.1% and 16.6 %, in women and men, respectively. 
In a national study conducted between January 2003 and January 2005 97, 49.8% of 
the participants (47.8% and 52.1%, respectively in women and men) presented WC ≥ 
80 cm and WC ≥94 cm, respectively for women and men. For higher cut-off points 
(WC ≥ 88 cm and WC ≥102 cm, respectively for women and men) a prevalence of 
24.9 % was found (24.6% and 25.3%, respectively for women and men). According to 
another Portuguese study 99, in which the cut-off points for AO were defined as WC 
values greater than 88 and 102 cm, respectively in women and men, women had a 
higher prevalence of AO than men (37.9% and 19.3%, respectively) in the participants 
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aged 18-64 years. Older adults (≥ 65 years) presented higher values (69.7% and 32.1%, 
respectively in women and men).  
Compared with other European countries 93, 109-124 (Table 4), and although the results 
in Portugal are quite diverse 97, 99, higher prevalence estimates for AO were observed 
in women, following the trend of most studies 93, 110-114, 116-119, 123. The national 
prevalence of AO, according to available estimates, is high compared to several 
European countries. Taking into account the worst estimates, the prevalence of AO in 
Portugal may be similar to that of the USA 125. In addition, compared with mean 
worldwide estimates, national results were also high 126. 
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Table 4.  Prevalence of abdominal obesity in Europe and Worldwide 
Country Study 
date 
Age  
(years) 
Men  
(94 cm) 
Men  
(102 cm) 
Women 
(80 cm) 
Women  
(88 cm) 
Portugal 108 1999-2003 ≥ 18  16.6  40.1 
Portugal 97 2003-2005 18-64 52.1 25.3 47.8 24.6 
Portugal 99 2008-2009 ≥ 18  19.3  37.9 
Spain 111 2008-2010 ≥ 18  31.7  39.2 
France 112 2006 ≥ 16  49.5  58.2 
France 113 2006 ≥18 42.3  51.6  
France 114 2013 30-69 41.6  48.5  
Italy 115 2007 ≥ 18  57.0  56.4 
Greece 116 2003 20-70 27.7 26.6 20.7 35.8 
England 93 2008 18-67 62.8 35.7 66.8 43.9 
Ireland 117 2011 18-64 22.5 31.1 26.6 37.3 
Germany 118 2008-2011 18-79 54.2 31.3 56.9 36.4 
Belgian 119 2014 40-70 37.2 28.7 50.0 23.6 
Denmark 120 2011-2012 Adults 40.2  35.7  
Norway 121 2006-2008 ≥ 20 31.9 31,9 23.7 55.9 
Sweden 122 2006 18-65 29.9 32.7 26.7 42.5 
Poland 123 2013-2014 ≥ 20 32.2 27.2 45.7 21.7 
Romania 110 2012-2014 20-79 68.9  73.9  
Russia 109 2000 18-90  6.3  29.0 
Europe 124 1992-2000 25-70  23.1  24.1 
USA 125 2007-2008 ≥ 20  43.4  61.6 
Worldwide 126   56.0 29.0 71.0 48.0 
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Taking into account data on AO in the Portuguese population, and the differences 
found in relation to other populations, it can be questioned if any of the two levels of 
WC cut-off points usually proposed are appropriate to the Portuguese reality. In 
addition, although the most recent MetS definitions have adopted WC as the 
anthropometric measure of adiposity, several other studies have suggested the use of 
other adipose measures, namely WHtR 56-58. 
There are few longitudinal studies that analyse the relationship between the different 
anthropometric measures of AO and the risk of CVD and diabetes by ethnic groups 
and by sex 1. In Portugal, no longitudinal study has yet been conducted with the 
objective of determining WC cut-off points as a function of the risk of CVD and 
diabetes. 
In order to choose the best anthropometric measure to estimate adipose tissue and 
respective cut-off points, several methodological procedures may be used in cross-
sectional studies. One of the proposed methods uses receiver operating characteristic 
(ROC) curves to compare the ability of anthropometric measures of AO to identify the 
MetS and to estimate the cut-off points that better identify MetS and corresponding 
CVD and diabetes risk, using the point that maximizes the sensitivity plus specificity 
94, 95. However, the strength of association of measures of AO with each of the 
components of MetS may vary according to the population studied 1. In addition, the 
predictive value of AO in the evaluation of the risk of CVD 127 and diabetes 128 varies 
according to its severity.  
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Although several cross-sectional studies have addressed AO, no national study has yet 
been conducted in order to estimate and to compare the cut-off points for several AO 
anthropometric measures that better identify the MetS. 
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3. Metabolic syndrome: prevalence in the World, Europe 
and Portugal 
MetS is a clinical entity that has reached a large and growing world dimension 129. This 
is not independent of the increasing prevalence of obesity, diabetes and sedentary 
lifestyles, on a global scale. 
In Portugal, the CVD risk factors included in the MetS definition by the JIS statement 
1 are highly prevalent. In fact, the national prevalence of overweight and obesity in 
Portugal is high 96-99 and shows a growing trend 100-102. In the adult national population, 
only less than 50% of the individuals present normal weight 102. The prevalence of 
hypertension and type 2 diabetes is also high in Portugal (42.2% and 11.7%, 
respectively) 130, 131.  
As expected, the prevalence of MetS is high in the Portuguese population 132-135. 
According to the various cross-sectional studies available, the prevalence of MetS 
ranged from 24.0% to 28.4%, 42% to 66%, and 37.2% to 69.4%, according to the ATP 
III, IDF criteria and JIS (WC European criteria), respectively.  
Comparing with other European countries, the national prevalence of the MetS is 
relatively higher than in Southern 136-149 (Table 5), Northern 150-159 (Table 6), Western 
160-172 (Table 7), and Eastern Europe (Table 8) 89, 173-190, with the exception of Greece 
143, Spain 137, Germany 168, Luxembourg 166, Croatia 175, Romania 178, Poland 186 and 
Turkey 190. According to two reports 191, 192 resulting from collaboration between 
several European centers involved in cross-sectional studies, the prevalence of MetS 
in Europe according to the ATP III definition was 23.9% to 25.9% in men and 23.4% 
to 24.6% in women.  
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Compared with other regions of the world, including North 193-198, Central 199 and 
South 200-204 America, Asia and Pacific 205-224, Middle East 225-241 and Africa 242-251, 
Portugal presents, in general, a higher prevalence of the MetS. In addition, Portugal 
presents estimates similar or slightly higher than those found in the United States 193-
195, 197, 198 and in Brazil 202.  
Several studies conducted around the world have shown differences between urban 
and rural populations (Table 9). In some cases, there was a greater prevalence in urban 
areas 208, 223, 252-256 while in others the opposite occurred 215, 257. The differences found 
between urban and rural populations have been partially explained by demographic 
and ethnic factors, as well as differences in eating habits and physical activity, among 
others 208, 215, 223, 241, 252-264, but studies carried out so far in Portugal, did not address 
the differences between urban and non-urban populations. 
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Table 5. Metabolic syndrome crude prevalence – Southern Europe 
Country 
Study 
date 
Sample 
size 
Age 
range 
MetS 
definition 
Men 
(%) 
Women 
(%) 
Total 
(%) 
Portugal 132 2005-2008 1433 ≥ 18 
ATP III 18.7 27.2 24.0 
IDF 37.8 44.4 41.9 
JIS (102/88 cm) 32.4 40.1 37.2 
Portugal 133, 135 2006-2007 16856 18-96 
ATP III 27.3 29.5 28.4 
IDF 60.1 70.4 65.5 
JIS (102/88 cm) b 65.6 72.8 69.4 
Portugal 134 2008-2009 5167 20-79 IDF   41.5 
Spain 136 2004-2008 2459 20-92 
IDF 19.2 12.1 15.0 
JIS (102/88 cm) 14.9 11.1 12.7 
Spain 137 2009-2010 4727 18-90 
IDF 40.2 37.4  
JIS (102/88 cm) 34.0 33.9  
Spain 138 2008-2010 11149 ≥18 JIS (102/88 cm) 26.0 19.4 22.7 
Greece 139, 140 2003-2004 4153 >18 ATP III b 
24.1 
24.2 a 
22.9 
22.8 a 
23.6 a 
Greece 141, 142 2003-2004 9669 >18 
ATP III b 24.8 a 24.2 a 
24.5 
24.5 a 
IDF   
43.1 
43.4 a 
JIS (102/88 cm)   26.3 a 
JIS (94/80 cm)   45.7 a 
Greece 143 2001-2002 3042 18-89 
IDF 53.0 45.0 48.9 
JIS (102/88 cm) 25.0 14.9 20.0 
Italy 144 1997-1999 2100 ≥ 19 ATP III 15.0 18.0 17.0 
Italy 145 2001 2388 ˃ 25 ATP III 29.0 23.4  
Italy 146, 147 2001 1929 40-79 ATP III b   22.5 
Italy 148 2001-2003 1564 45-64 ATP III   21.7 
Italy 149 2003-2004 345 ˃65 ATP III b 27.6 28.2 27.9 
ATP III, National Cholesterol Education Program (NCEP) Adult Treatment Panel III; IDF, International 
Diabetes Federation; JIS, Joint Interim Statement; MetS, metabolic syndrome. 
a Age-standardized prevalence of the MetS; b Modified classification. 
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Table 6. Metabolic syndrome crude prevalence – Northern Europe 
Country 
Study 
date 
Sample 
size 
Age 
range 
MetS 
definition 
Men 
(%) 
Women 
(%) 
Total 
(%) 
    IDF 44.7 39.1  
Finland 150 2000-2001 6105 30-79 JIS (102/88 cm) 36.9 34.5  
    JIS (94/80 cm) 47.8 40.7  
Finland 151 2000-2001 6093 30-79 ATP III 30.2 31.2 30.8 
Finland 152 2004 3407 18-78 IDF   31.3 
Sweden 153 1991-1994 2064 45-69 ATP III   19.9 
Sweden 154 2002-2006 17544 45-64 
ATP III   29.2 
IDF   45.2 
JIS (94/80 cm)   47.9 
Norway 155 1995-1997 10206 20-89 
IDF 29.0 30.3 29.6 
JIS (102/88 cm) 26.8 25.0 25.9 
Denmark 156 2007-2008 15235 18-93 IDF b   27.0 
Denmark 157 2001-2003 5801 20-97 ATP III b 20.0 20.0 20.0 
Denmark 158 2003-2011 71527 20-100 JIS (94/80 cm) b 38.3 23.1 29.7 
Estonia 159 2008-2009 495 20-74 JIS (102/88 cm) 
30.8 
29.4 a 
25.6 
23.8 a 
27.9 
25.9 a 
 
ATP III, National Cholesterol Education Program (NCEP) Adult Treatment Panel III; IDF, International 
Diabetes Federation; JIS, Joint Interim Statement; MetS, metabolic syndrome. 
a Prevalence of MetS weighted for the average Estonian population (estimated in 2009); b Modified 
classification. 
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Table 7. Metabolic syndrome crude prevalence – Western Europe 
 
ATP III, National Cholesterol Education Program (NCEP) Adult Treatment Panel III; IDF, International 
Diabetes Federation; JIS, Joint Interim Statement; MetS, metabolic syndrome. 
a Participants without CVD or diabetes; b Age-standardized prevalence according to the German 
population; c Modified classification. 
 
  
Country 
Study 
date 
Sample 
size 
Age 
range 
MetS 
definition 
Men 
(%) 
Women 
(%) 
Total 
(%) 
France 170 2006-2007 1856 18-74 
ATP III c 14.4 13.7 14.1 
IDF 21.3 19.3 20.3 
JIS (94/80 cm) 22.8 19.4 21.1 
JIS (102/88 cm) 17.5 15.7 16.6 
France 161 2011-2012 7902 >18 JIS (94/80 cm) 18.9 9.5 12.2 
Nederland 162 2006-2012 59467 18-80 JIS (102/88 cm) 21.0 13.2 16.4 
Nederland 163 2008 1592 20-80 IDF   7.3 
Nederland 164 2006 14005 20-70 ATP III   15.5 
Belgium 165 2002-2004 992 a 18-75 IDF 12.7 8.5  
Luxembourg 166 2007-2008 1349 18-69 
JIS (94/80 cm) 35.5 20.4 28.0 
JIS (102/88 cm) 30.8 18.5 24.7 
IDF 31.0 19.3  
Switzerland 167 2003-2006 4231 35-75 ATP III c 22.8 13.7 18.0 
Germany 168 2005 35869 18-99 
ATP III 
22.7 
19.5 b 
18.0 
18.1 b 
19.8 
18.7 b 
IDF 
40.3 
34.1 b 
28.0 
27.7 b 
32.7 
30.7 b 
JIS (102/88 cm) 
34.8 
29.2 b 
24.8 
24.8 b 
28.6 
26.9 b 
UnitedKingdom 169 2003-2004 6073 ˃ 48 ATPIII   13.6 
United Kingdom 170 1988-1990 1787 40-69 IDF   23.1 
United Kingdom 171 2002-2004 6810 45 JIS (102/88 cm) c  9.6 8.1  
Ireland 172 2003-2005 1716 32-78 
ATP III 15.8 9.3 13.2 
IDF 26.4 14.0 21.4 
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Table 8. Metabolic syndrome crude prevalence – Eastern Europe 
Country 
Study 
date 
Sample 
size 
Age 
range 
MetS 
definition 
Men 
(%) 
Wome
n (%) 
Total 
(%) 
Croatia 173 2008 2466 ≥ 40 IDF   60.8 
Croatia 174 2002-2003 996 >18 ATP III e 28.0 39.0 34.0 
Croatia 175 2001 1394 20 
ATPIII 28.3 23.2 25.0 
IDF 42.9 35.9 38.5 
Slovakia 176 2003-2005 1517 ˃18 
ATP III 15.9 23.9 20.1 
IDF 39.7 36.6 38.1 
Czech Rep177 2004-2006 805 18-65 IDF 32.5 22.9 26.4 
Romania 178 2005 1176 a 18 
ATP III 38.3 42.3 40.6 
IDF 43.1 45.3 44.2 
Romania 179 
Published 
2009 
1294 18-79 IDF 57.8 28.8 45.7 
Romania 110 2012-2014 2681 20-79 JIS (94/80 cm) 43.2 34.2 38.5 
Bulgaria 180, 
181 
2005-2008 575 b 19-98 
ATPIII 23 23 23 
IDF 30 36 33 
Bulgaria 182 2005 2415  20 IDF 37.1 25.9 30.8 
Hungary 183 2006 1803 20-69 
ATP III e 26.0 24.0  
IDF 37.0 30.0  
JIS (94/80 cm) 
39.0 
38.0 c 
31.0 
30.0 c 
 
Hungary 184 2005 1762 20-69 IDF 39.3 33.9 36.4 
Poland 185 2003-2005 12567 20-74 
IDF 30.7 26.8 28.6 
JIS (102/88 cm) 26.0 23.9 24.9 
Poland 186 
Published 
2010 
1648 25-85 
JIS (102/88 cm) 38.6 39.0  
IDF 49.9 43.9  
Russia 187 2000 3555 18-90 
ATP III e 10.0 21.0 15.0 
IDF e 9.5 23.5 15.9 
Turkey 188 2003-2005 767 20-83 ATP III 23.1 33.5 28.8 
    IDF 31.2 37.3 34.6 
Turkey 189 
Published 
2007 
4259 20 ATP III e 28.0 39.6 33.9 
Turkey 190 2003 1568 d 20 JIS (102/88 cm) 41.0 43.0 38.0 c 
    IDF 46.0 48.0 42.0 c 
ATP III, National Cholesterol Education Program (NCEP) Adult Treatment Panel III; IDF, International 
Diabetes Federation; JIS, Joint Interim Statement; MetS, metabolic syndrome. 
a Patients with CVD; b Subjects without personal or family history of CVD, hypertension or diabetes 
mellitus; c Age-adjusted prevalence of the MetS; d Non-diabetic participants; e Modified classification. 
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Table 9. Urban versus rural (or non-urban) metabolic syndrome crude 
prevalence 
 
ATP III, National Cholesterol Education Program (NCEP) Adult Treatment Panel III; IDF, International 
Diabetes Federation; JIS, Joint Interim Statement; MetS, metabolic syndrome; T, total; M, men; W, 
women; A, agricultural; NA, non-agricultural; NS, not significant; NA, not available. 
a Modified classification. 
 
Country  
Study 
date 
Sample 
size 
Age 
group 
MetS 
definition 
Rural 
(%) 
Urban 
(%) 
p-
value 
Spain 258 2000-2003 809 35-74 JIS (102/88 cm) a 20.3 15.5 NS 
Germany 259 
Published 
2017 
3863 18-65 ATPIII 
M - 13.3 
W - 6.3 
M - 6.7 
W - 6.1 
˂0.05 
NS 
USA 257 1999-2006 6896 ≥ 20 JIS (102/88 cm) a 
T - 39.9 
M - 39.7 
W - 40.2 
T - 32.8 
M - 33.3 
W - 32.3 
˂0.01 
˂0.05 
˂0.01 
Palestine 260, 261 1996-1998 992 30-65 WHO a 17.0 17.0 NS 
United Arab 
Emirates 241 
1999-2000 4097 ≥ 20 
JIS (94/80 cm) a 
 
T - 44.9 
M - 37.3 
W - 49.0 
T - 38.2 
M - 34.7 
W - 41.0 
0.010 
IDF 
T - 44.3 
M - 39.1 
W - 47.3 
T - 39.6 
M - 36.8 
W - 42.0 
0.159 
Chine 208 2000-2001 15540 35-74 ATP III a 12.7 18.6 ˂0.05 
India 252 1991-1995 4044 35-64 ATP III 
T - 11.1 
M - 10.6 
W - 11.6 
T - 30.2 
M - 26.8 
W - 33.4 
˂0.001 
Nigeria 253 
Published 
2017 
535 18-89 
ATP III 13.7 28.2 ˂0.001 
IDF 12.2 30.8 ˂0.001 
JIS (94/80 cm) 12.2 33.3 ˂0.001 
Cameroon 254  1573 24-74 WHO 
M – 1.9 
W – 1.8 
M - 7.3 
W - 5.9 
0.001 
0.002 
Ghana 255 
 
2002-2008 2220 18-99 ATP III a 
M - 7.8 
W - 11.2 
M - 12.6 
W - 21.4 
NS 
˂0.05 
Thayland 223 2008-2009 19256 ≥ 20 JIS (90/80 cm) 
M - 17.9 
W - 27.7 
M - 23.1 
W - 24.5 
˂0.05 
˂0.05 
Malasya 215 2007-2011 8836 ≥ 30 
ATP III 28.5 25.0 0.001 
IDF 36.3 39.0 0.002 
JIS (90/80 cm) 42.5 44.6 0.018 
Guatemala 263 2002-2004 887 25-42 JIS (102/88 cm) 
M (A) - 17.1 
M (NA) - 23.5 
W - 44.1 
M - 27.7 
 
W - 44.5 
NS 
 
NS 
Colombia 256 1994-1996 615 ≥ 30 WHO a 
M - 2.8 
W - 17.9 
M - 14.1 
W - 26.0 
˂0.01 
NS 
Brazil 262 2013 435 ≥ 60 ATP III a 
M - 22.0 
W - 37.0 
M - 13.0 
W - 40.0 
NA 
NA 
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4. Metabolic syndrome associated risk: cardiovascular 
disease and type 2 diabetes 
 
4.1. Physiopathology 
The concept of IR was introduced in 1936 by Himsworth who suggested its 
relationship with diabetes mellitus 265. Following the description in 1959, by Yalow 
and Berson, of an immunoassay technique for insulin, the theory of Himsworth was 
reinforced, by evidence of hyperinsulinism in individuals with hyperglycaemia 266.  In 
the 1960s, several authors 73, 267-270 reported associations between various risk factors 
for CVD that are now part of the metabolic syndrome. Even in the 1960s, associations 
of hyperinsulinism with CVD risk factors, other than hyperglycaemia, were reported 
271-275. In the 1970s and early 1980s, following the description of techniques to measure 
IR 276, 277, the concept of the association of several risk factors with each other 74, 76, 278-
281 and with IR 75, 276, 279, 280, 282, 283 was reinforced. 
With the introduction of “syndrome X” in 1988, by Reaven 12, IR was considered the 
key piece in the development of the syndrome. Although obesity was stressed as 
exacerbating factor, it was not recognized with the same pathophysiological 
significance of IR. In contrast, Kaplan, in 1989, included obesity in the “deadly 
quartet” 69. Obesity would play a central role and IR would be a key intermediary in 
the pathogenesis of MetS. In the following years, the controversy was established 
regarding the relative importance of IR and obesity in the etiopathogenesis of MetS.  
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Being caused or not by obesity, IR may contribute through several mechanisms for the 
etiopathogenesis of the risk factors that integrate MetS as well as for the risk of CVD 
and type 2 diabetes 284-286. 
The theory of lipotoxicity, based on the harmful effects of circulating free fatty acids 
(FFA) on insulin sensitivity 287-289, has been gaining consistency. FFAs are 
hydrophobic and thus circulate in the blood largely bound to albumin. The FFA 
originate mainly in the adipose tissue triglycerides deposits, through the action of three 
different hydrolases: adipose triglyceride lipase (ATGL or Pnpla2), hormone-sensitive 
lipase (Hsl) and monoglyceride lipase. Additionally, the FFA may also come from 
hydrolysis of triglyceride-rich lipoproteins in the vascular endothelium of peripheral 
tissues, mainly adipose and muscle tissue, through lipoprotein lipase (LPL) activity 
290. Insulin counteracts the release of FFA from adipose tissue and stimulates the LPL 
activity. Nevertheless, under IR conditions, the lipolytic effect in the adipose tissue, 
mainly related to ATGL hyperactivity 291 may predominate over LPL reduced action 
292-294, and circulating FFA may increase.  
The increase of lipolysis in adipose tissue is also associated with an increase in local 
inflammatory phenomena, reflected by an increase in macrophages and by the 
production of adipokines 295, 296. According to the lipotoxicity model, increased 
circulating FFA may contribute to the aggravation of IR in insulin-sensitive tissues, 
namely in skeletal muscle and liver. However, FFA lipotoxicity can also manifest in 
other tissues with ectopic deposits of fat and contribute locally to the IR in these 
tissues. 
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Muscle tissue is the body's main site of insulin-mediated uptake of glucose. From the 
point of view of energy reserves, the skeletal muscle stands out due to its important 
glycogen and triglyceride deposits 297. In states of muscular IR, the uptake of glucose 
is reduced, the production of glycogen is decreased, and the production of triglycerides 
is increased. 
According to the glucose-fatty acid cycle, proposed by Randle 298, increased FFA 
muscular input may lead to a switch in fuel metabolism from carbohydrate to fat 
oxidation. FFA besides competing with glucose as the main source of energy in the 
muscle, may still contribute to hyperglycaemia by interfering with insulin mediated 
glucose uptake. FFA can cause muscle IR through interference with multiple signalling 
pathways 288, 299 by activating several protein kinases C (PKC) isoforms 300, 301, through 
the increase of intracellular levels of diacylglycerol (DAG) with subsequent 
suppression of tyrosine phosphorylation of the insulin receptor substrate 302, 
decreasing activation of phosphatidylinositol 3-kinase (PI3K), and thus reducing 
GLUT4 translocation, culminating in a reduction of muscle glucose uptake 303. 
Moreover, other bioactive lipid metabolites such as long-chain fatty acyl CoA (the 
activated form of intracellular FFA) and ceramides 304 may interfere with normal 
insulin signalling and aggravate IR 305.  Glycogen synthesis, the non-oxidative glucose 
metabolism pathway, is activated by insulin. Under muscle IR conditions glycogen 
storage is compromised by decreased glucose uptake and decreased glycogen synthase 
activity 299. In addition, the increased triglycerides content of the muscle in IR states, 
may result from a mismatch between the oxidation capacity and the increased 
availability of FFA 297.  
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As a consequence of IR, particularly in adipose tissue, the excessive supply of 
circulating FFA to the liver, may lead to an increase in intracellular FFA. The rate of 
FFA uptake from blood into hepatocytes depends on their concentration and 
intracellular transport capacity, namely through fatty acid transport proteins (FATP), 
as well as the ability to dissociate FFA from albumin 306. As in muscle, increased 
hepatic FFA may interfere with insulin activation of the insulin receptor substrate 
through the activation of PKC isoforms and subsequent suppression of insulin receptor 
substrate tyrosine phosphorylation 307.  Under normal circumstances, the liver is the 
main source of endogenous glucose production. In the fasting state, where blood levels 
of insulin are usually low, the liver contributes to the maintenance of glucose 
homeostasis through increased glucose output. The hepatic output of glucose is 
ensured through the stimulation of glycogenolysis and gluconeogenesis. However, in 
an IR environment 308, the postprandial insulin-induced inhibition of gluconeogenesis 
and glycogenolysis, is compromised, leading to the endogenous production of glucose 
at the expense of gluconeogenesis and glycogenolysis, and as a result, hepatic output 
of glucose may increase 309. Thus, in addition to adipose tissue, the liver also 
contributes to increased blood levels of glucose.  On the other hand, the decrease in 
muscle uptake of glucose, due to IR, leads to a greater availability of glucose in the 
liver for the de novo lipogenesis 310 and consequent increase in the hepatic synthesis 
of triglycerides 311. Hepatic de novo lipogenesis is a biosynthesis pathway of 
triglycerides from acetyl-CoA, which can be originated by several metabolic 
pathways, namely glycolysis. In addition to glucose, fructose is also a strong lipogenic 
substrate. The transcriptional regulation of de novo lipogenesis is mediated by the 
sterol regulatory element binding protein 1c (SREBP1c) and carbohydrate response 
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element binding protein (ChREBP). Hyperinsulinism, secondary to IR, may have a 
major contribution to the activation of de novo lipogenesis, through increased 
expression of hepatic SREBP1c which regulates the transcription of various enzymes 
involved in lipogenesis 312. 
FFA, in addition to its action on IR, is still the major substrate for hepatic triglyceride 
synthesis 313, 314. Although there are some manifestations of IR in the liver, lipogenesis 
continues to be stimulated by insulin 315, 316. After entering into cells, FFA are rapidly 
activated by conversion to fatty acyl CoAs and then either oxidized or processed to 
triglycerides and stored.  
FFA can be converted in the liver, through β oxidation and ketogenesis, in ketone 
bodies, an important energy source in the fasting state 317. Increased liver glucose 
uptake and a possible decrease in AMP-activated protein kinase (AMPK) activity, an 
inhibitor of malonyl-CoA synthesis 318, may increase the intracellular levels of 
malonyl-CoA. Increased malonyl-CoA levels may lead to a decreased oxidation of 
fatty acids and to increased lipogenesis and intracellular DAG levels 319-322 which can 
activate PKC 323. 
Increased hepatic triglyceride deposition leads to increased synthesis of apolipoprotein 
B-100 containing, very low-density lipoprotein (VLDL) 324 and subsequent increase 
in circulating VLDL and blood levels of triglycerides. The increase in circulating 
VLDL concentration associated with a normal activity of cholesteryl ester transfer 
protein (CETP) leads to an increase in triglyceride exchanges of VLDL by cholesterol 
of HDL. This process leads to a cholesterol-rich VLDL remnant particle that is 
atherogenic. On the other hand, the triglyceride-rich and low-cholesterol HDL 
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particles may undergo further hydrolysis of triglycerides and the dissociation of apo 
A-I protein. The free apo A-I in plasma is cleared more rapidly than apo A-I associated 
with HDL particles, leading to a reduced amount of circulating apo A-I and HDL 
particles, as well as lower HDL cholesterol levels. 
Under physiological conditions, the FFA stimulate insulin secretion, namely in the 
basal status and potentiate glucose-stimulated insulin secretion 309. Nevetheless, 
increased circulating FFA may be lipotoxic to beta cell and lead to a decrease in insulin 
secretion. Moreover, hyperglycaemia, resulting from decreased peripheral utilization 
and increased hepatic output, may contribute to decreased pancreatic insulin secretion 
through glycotoxicity. 
In addition to the mechanisms proposed for the association of IR with hyperglycaemia, 
hypertriglyceridemia and low HDL cholesterol, IR and/or associated secondary 
hyperinsulinism may also contribute to BP elevation. 
IR may contribute to the development of hypertension due to loss of the vasodilator 
effect of insulin 325 and pressor effect of FFA 326-328. Likewise, secondary 
hyperinsulinism, due to IR, can promote hypertension 329-331 through several 
mechanisms that include: chronic enhancement of sympathetic nervous system 
activity, stimulation of the renin-angiotensin-aldosterone system (RAAS), modulation 
of cation transport and inducing vascular smooth muscle cell hypertrophy. 
IR can also contribute to CVD risk by induction of a prothrombotic state and release 
of pro-inflammatory cytokines from the adipose tissue 332.  
Adding to previously mentioned IR-related mechanisms, obesity itself  may contribute 
to the etiopathogenesis of the various risk factors that integrate MetS. Obesity-related 
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IR is mainly due to the expansion of the adipose compartment and increased release 
of FFA 288, 333. Subcutaneous adipose tissue (SAT) is an adipose compartment with 
lower cardiometabolic risk than VAT or other non-SAT locations, such as the liver 
and skeletal and cardiac muscle 334. In fact, several studies have shown an association 
of non-SAT deposits, with a high risk for CVD 335 and diabetes 336. The contribution 
of visceral fat deposits to IR is greater than that of subcutaneous fat, namely in women 
337, 338. The visceral lipolysis, according to the portal hypothesis, leads to an increased 
supply of FFA to the liver through the splanchnic circulation, which leads to greater 
liver exposure to FFA. In addition, VAT is also more metabolically active 336,339. It is 
more sensitive to lipolysis and produces more inflammatory cytokines 340. 
The association of adiposity, namely VAT, with hypertension is well documented 341, 
342. The retroperitoneal component of the VAT, which includes peri-renal fat, may also 
have a greater association with hypertension 343. The association of obesity with 
hypertension may be explained by several mechanisms 337, 344, 345. Reduced renal 
reabsorption of sodium and increase intravascular volume may be related to 
hyperinsulinism secondary to IR 346, 347. Expanded adipose tissue, namely VAT and 
perivascular adipose tissue, may lead to the increased local production of 
angiotensinogen and activation of the RAAS 348-350. Angiotensin II is also produced in 
adipose tissue not only by the usual route of RAAS but also by cathepsins and chymase 
351. In addition to adipose tissue synthesis, increased blood levels of angiotensinogen 
and angiotensin II have also been documented in obesity 352. Adipocytes also produce 
aldosterone and increase vascular stiffness through vascular mineralocorticoid 
receptors 353. Mineralocorticoid receptors are also present in adipose tissue and may 
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contribute to the synthesis of inflammatory adipokines and to the mediation of 
adipogenic actions of aldosterone and glucocorticoids 353, 354. 
Sympathetic nervous system (SNS) 344, 355-361 activation, namely renal 362, may also 
play an important role in obesity 355, 356, 363, 364 Increased leptin 359, 365, secondary 
hyperinsulinism, impaired baroreflex sensitivity and brain RAAS may contribute to 
the enhanced SNS activity when obesity is present 366, 367. 
Finally, obesity may influence several CVD risk factors through inflammation 368. 
Adipokines are hormones produced in adipose tissue and may have multiple local and 
systemic actions. Adipokines produced in perivascular adipose tissue, primarily have 
local paracrine actions 369-371. On the contrary, some of the adipokines produced at the 
usual adipose sites, namely in the VAT, can have a systemic contribution to the chronic 
inflammatory process. Some of the adipokines and cytokines produced locally may 
have pro-inflammatory actions (TNFα, IL-6, leptin, visfatin, resistin, adipocyte fatty-
acid-binding protein, chemerin, C-reactive protein, retinol binding protein 4, SAA3, 
PAI-1 ) contributing to the adiposity-related, IR and/or to CVD or diabetes risk 36, 337, 
372-374.  As contrast, others may have anti-inflammatory actions (omentin, apelin, 
adiponectin, fibroblast growth factor 21 and vaspin) and may be protective 368. Obesity 
can trigger a positive imbalance between adipokines with harmful cardiovascular 
action and protective adipokines, thus leading to an increase in cardiovascular risk 375.  
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4.2. Cardiovascular disease risk 
MetS is associated with an increased risk of CVD 376-380. According to several meta-
analyses 377, 378 the risk may even be higher for the WHO than for the ATP III 
definition. A systematic review including studies published from 1998 to 2005 377, 
estimated a relative risk (RR) for CVD of 1.65 (95%CI: 1.38-1.99) and 1.93 (95%CI: 
1.39-2.67), according to ATP III and WHO definitions, respectively. In addition, the 
RR for CVD may be higher in women compared with men 378. MetS is also associated 
with an increased CVD mortality 378, 379, 381, namely in women. According to a 
systematic review and meta-analysis including prospective observational studies from 
2002 to 2009 381, the estimated RR for CVD mortality was 2.51 (95% CI: 1.38-4.55) 
and 1.93 (95% CI: 1.56-2.40), according to ATP III (2001) and AHA / NHLBI / ADA 
(2004), respectively. The MetS has also been associated with subclinical 
atherosclerotic disease, as several studies found significant associations between MetS 
and subclinical carotid damage, based on measurements of carotid intima-media 
thickness 382. 
The MetS associated risk for CVD may be increased by the number of its individual 
components present. According to a USA study 383, the risk was significantly increased 
when 3 [OR 2.70 (95%CI:1.22-5.98)] and 4 or more [OR 5.86 (95%CI:2.51-13.66)] 
components were present.  
Newer definitions such as IDF, AHA/NHLBI 2005 and JIS, lowered the thresholds for 
several of the MetS components and included treated individuals in each individual 
component, increasing this way the prevalence of the MetS compared with older 
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definitions, resulting in lower reported risks of CVD and associated mortality 192, 384-
391.  
The CVD risk associated with MetS may also be related to type 2 diabetes risk 392-394. 
A meta-analysis of 102 prospective studies 393, found an increased risk for coronary 
heart disease (CHD) [hazard ratio (HR) 2.00 (95%CI:1.83-2.19)] in diabetic subjects. 
Even in individuals with no diabetes criteria, the presence of IFG increased the risk of 
CVD. According to a recent systematic review 395, impaired fasting glucose, defined 
by 100 mg/dL 396 or 110 mg/dL 397 cut-off points, increased the risk for CVD [RR 1.18 
(95%CI:1.09-1.28) and RR 1.20 (95%CI:1.12-1.28) respectively], and the occurrence 
of  diabetes 392 and IFG 394 may be related to the increased risk of  CVD risk in women.  
Hypertension may also play an important role in MetS-associated risk for CVD. In 
fact, high BP is a major cause of CVD risk 398-401 and mortality 402-406. The CVD risk 
may even be higher in women 398. The BP component of the MetS (≥ 130/85 mm Hg), 
in addition to its association with arterial stiffness 407 and carotid atherosclerosis 408, 
may also increase CVD risk .409-411. In fact, the Framingham Offspring Study 409 
showed a RR for CVD of 2.0 (95%CI:1.4-2.9) in participants with the BP component, 
compared with those who did not present the trait. Furthermore, the BP component 
was associated with CVD mortality 411, 412.  According to a Japanese study 412, the HR 
for CVD mortality was 2.07 (95%CI:1.21-3.52) in subjects with the blood component 
compared with those who did not present it.  
Triglycerides and HDL cholesterol, the lipidic components of the MetS may also play 
an important role in the CVD risk. Triglycerides are inversely associated with HDL 
cholesterol 413, making it difficult to isolate each one`scardiovascular effects. In fact, 
  
Background | 36 
 
the strength of the association of triglycerides with CVD risk was greater if HDL was 
low 414, 415. In contrast to triglycerides, low HDL cholesterol is a well-established 
independent risk factor for CVD 416. The role of triglycerides on atherogenic risk was 
stressed by Lemieux with the use of the term “hypertriglyceridemic waist” 417. 
Triglyceride levels are associated with increased CVD risk 418-427, namely in women 
423. This association has been supported by several meta-analyses 421, 423, 426.  The 
strength of the association may be greater in subjects with impaired glucose tolerance 
or type 2 diabetes 428, 429. Randomized controlled trials suggested a stronger association 
of glucose, HDL cholesterol and BP components of MetS with CVD risk, over 
triglycerides trait 386, 430-433. According to these data, the triglycerides component may 
play an important role as a biomarker rather than as a risk factor for CVD. However, 
in the NHANES study, the triglycerides MetS component had a stronger association 
with CHD risk [OR 1.66 (95%CI:1.20-2.30), than the other components, namely HDL 
component [OR 1.35 (95%CI:105-1.74)] 434.  
Obesity is independently associated to CVD risk 21, 22. In addition, AO may even be a 
better risk predictor than total body fat 28. In the Botnia study 411, the adiposity 
component of MetS (according to WHO definition) was significantly associated with 
CVD risk [RR 1.44 (p=0.07)], but dyslipidemia and BP components showed stronger 
associations. The Framingham Offspring Study 409 also showed an increased risk of 
CVD [RR 1.9 (95%CI:1.4-2.5)] for AO (according to ATP III definition) but weaker 
than for the glucose and BP components. On the other hand, a study of elderly Danish 
women 410 reported a significant association of CVD risk only with the AO 
(central/peripheral fat mass rate ˃ 1 or BMI ˃30 Kg/m2) and BP components [HR1.48 
(95%CI: 1.30, 1.48) and HR 1.19 (95%CI: 1.09, 1.30), respectively].  
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4.3. Type 2 diabetes risk 
MetS is a risk factor for type 2 diabetes 377, 435, 436. According to a meta-analysis, 
including prospective observational studies from 1998 to 2008 436, the RR for diabetes 
was 5.17 (95%CI;3.99-6.69), 4.45 (95%CI:2.41-8.22), 3.53 (2.84-4.39), 5.12 
(95%CI:3.26-8.05) and 4.42 (95%CI:3.30-5.92), for WHO, EGIR, ATP III, 
AHA/NHLBI 2005 and IDF definitions, respectively. 
As observed for CVD risk, the risk of type 2 diabetes may be higher with increasing 
number of components present 383, 409, 437. An USA study 383, found a significant 
increased risk for the presence of 2 [OR 5.99 (95%CI:1.44-24.98)], 3 [OR 9.37 
(95%CI: 2.22-39.59)] and 4 or more [OR 33.67 (95%CI:7.93-142.96)] components. In 
addition, the risk by number of MetS traits, according to glucose component status, is 
greater for all 4 possible traits grouping when this component is present 437. In fact, 
according to the Framingham Offspring Study 409 the glucose component alone, has 
more predictive value for type 2 diabetes risk [RR 12.5 95%CI:9.1-17.3)] than any 
trait grouping of 3 of the other 4 components [(RR 5.0 (95%CI:3.7-6.8)] of MetS. 
According to the Framingham Offspring Study 409, although the BP component 
increased the risk of diabetes [RR 2.4 (95%CI:1.7-3.5)], the magnitude of the 
association was lower than that for the other MetS components (RR between 2.7 and 
12.5). However, a Japanese study 437 showed that the BP component was in fact 
associated with diabetes risk even in normoglycemic subjects [HR 1.8 (95%CI:1.4-
2.5)]; in addition, this association increased substantially in subjects with impaired 
fasting glucose [HR 17.4 (95%CI:14.2-21.3)]. 
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Triglycerides levels are often high in type 2 diabetes 438. Furthermore, triglycerides 
levels may increase the risk of diabetes 439-441. According to a recent study 442 the risk 
of diabetes and impaired fasting glucose was increased by 4% and 2%, respectively, 
for every 10 mg/dL elevation of the triglycerides levels. Nevertheless, Mendelian 
randomization studies 443 suggested that triglycerides may soley be a biomarker and 
not a causal factor. 
HDL cholesterol levels are also associated with increased risk of diabetes in 
epidemiological studies 444-445. However, as for triglycerides, Mendelian 
randomization studies do not support a causal role for HDL cholesterol 446. 
Obesity is independently related to type 2 diabetes 29. Excluding the glucose 
component, the adiposity one appears to be more strongly associated with diabetes risk 
than other components 383, 409, 410, 437. The Framingham Offspring Study 409 showed a 
RR for diabetes of 4.1 (95%CI: 3.0, 5.6) in subjects with the AO component, compared 
with individuals without this trait, being only exceeded by the glucose component [RR 
12.5 (95%CI: 9.1, 17.3)]. In addition, according to a study of elderly Danish women 
410, AO and glucose components were the only ones that were associated with type 2 
diabetes [HR1.98 (95%CI: 1.57, 2.48) and HR 3.38 (95%CI: 2.71, 4.22), respectively]. 
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5. The metabolic syndrome: endocrine disorders 
The endocrine system has a main role in the energetic balance, BP and glucose and 
lipid levels 447- 452. Additionally, insulin sensitivity is dependent on complex endocrine 
regulation mechanisms. Thus, from this point of view, the MetS itself can be 
envisioned as an endocrine disease. 
Several rare endocrine disorders have been related to MetS, CVD and diabetes risk, 
namely acromegaly and Cushing syndrome. Increased production of growth hormone 
in acromegaly is associated with IR 453, 454, dyslipidaemia 455, hypertension 455, CVD 
455, 456 and diabetes risk 457-459. Cushing syndrome is associated with AO 460, MetS 461-
464, dyslipidemia, hypertension and increased risk of CHD 465-467 and diabetes 468. 
Among the endocrine diseases that have been associated with the MetS, thyroid 
diseases and hypovitaminosis D are highlighted due to their high prevalence.  
Although several studies have reported an association of MetS with hypovitaminosis 
D and thyroid dysfunction, namely hypothyroidism, the evidence is scarcer as far as 
thyroid autoimmunity is concerned. In Portugal, apart from the fact that no study has 
yet been published on the subject of MetS and its possible associations with 25(OH)D, 
thyroid-stimulating hormone (TSH), thyroid hormones and thyroid antibodies serum 
levels, there is little data available on hypovitaminosis D, thyroid dysfunction and 
thyroid autoimmunity. Thus, the approach of this specific endocrine pathology, in the 
context of the investigation of MetS in Portugal, aims to contribute not only to the 
clarification of its association with cardiometabolic risk but also to a better 
characterization of its national prevalence. 
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5.1. Vitamin D and the Metabolic Syndrome 
Vitamin D (VitD),  is actually a fat-soluble hormone with multiple actions, notably 
those involving calcium homeostasis and bone metabolism 469. Its cellular action is 
exerted through the binding to the nuclear VitD receptor (VDR), expressed in the 
majority of cells and with important effects on the regulation of the transcription of 
multiple genes. 1alpha, 25-dihydroxyvitamin D (1α,25(OH)2D) or calcitriol, the 
physiologically active form of VitD is produced from two prohormones, 
cholecalciferol (VitD3) and ergocalciferol (VitD2). VitD3, the main source of VitD, 
originates mainly in the skin where it is synthesized through photolytic conversion, 
from the cholesterol precursor 7-dehydrocholesterol, through exposure to ultraviolet 
(UV) B radiation (290-315 nm). A small part also comes from the diet. On the other 
hand, VitD2 comes exclusively from dietary sources. These forms of VitD are not 
biologically active and must undergo two hydroxylations to be active. The first step in 
VitD activation occurs in the liver through a 25-hydroxylation, with the formation of 
25-hydroxyvitamin D [25(OH)D], also known as calcidiol, which has low bioactivity 
but is the main form of VitD in the blood stream and the best indicator of VitD status. 
In a second activation step, 25(OH)D undergoes a 1α-hydroxylation, primarily in the 
kidney, leading to the synthesis of the active 1α,25(OH)2D. 
There is general agreement that the lower limit of an adequate VitD status corresponds 
to a serum 25 (OH) D value of 10-12 ng/mL (or 25-30 nmol/L) 470. Levels greater than 
or equal to 10-12 ng/mL have a beneficial effect on bone health by preventing rickets 
and osteomalacia. According to the Institute of Medicine (IOM) recommendations 471, 
serum levels of 25(OH)D between 12 and 20 ng/mL (or between 30 and 50 nmol/L) 
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are “inadequate” in some people. In addition, serum levels ˃20 ng/ml (or 50 nmol/L) 
are “sufficient” for almost the whole population. Nevertheless, there is still an intense 
discussion about optimal 25(OH)D values to not only maintain bone health but also 
other body systems influenced by VitD 472.  
Studies conducted in Portugal, to assess the prevalence of hypovitaminosis D had a 
regional scope and in most cases involved specific groups recruited in a hospital 
context. 
According to a study performed in a hospital in the North of Portugal 473, which 
included 5439 25(OH)D assays, a median of 17 ng/mL was found for 25(OH)D values; 
in addition, values ≤ 20 ng/mL were found in 60.3% of the cases. Another study 
performed in the Center of Portugal 474, including 123 hospitalized patients, showed a 
prevalence of 25(OH)D values less than 10 ng/mL or less than or equal to 20 ng/mL 
of 67.5% and 92.7%, respectively. Furthermore, another study also performed at a 
hospital in Center of Portugal 475, including 2071 25(OH)D assays, found a mean value 
of 11 ng/mL and a prevalence of 65% for 25(OH)D values below 20 ng/mL. A study 
conducted with 198 healthy volunteers aged 18-67 years in the city of Porto 476 showed 
mean levels of 22.2 ng/mL (or 55.4 nmol/L) for 25(OH)D; additionally, 48% of the 
participants presented levels below 20 ng/mL (74% in the winter period). According 
to a recent study of the EPITeen project 477, including 514 adolescents from the city of 
Porto, the mean value of 25(OH)D was 16.5 ng/mL.  
According to a systematic review on the worldwide prevalence of hypovitaminosis D 
478, that did not included Portugal, there was a large dispersion of mean and median 
values estimates for 25(OH)D (4.9 to 136.2 nmol/L and 20.7 to 91.0 nmol/L, 
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respectively). In addition, 37.3 % and 6.7% of the samples included in this review 
presented mean levels below 20 ng/mL and 10 ng/mL, respectively. Taking these 
values into account, hypovitaminosis D gains a worldwide dimension 470, 478.  
In addition to the effects on bone health, an inadequate vitD status has been associated 
with the CVD risk 479-490.  Hypovitaminosis D is also associated with subclinical 
atherosclerosis 491, 492. This association with the CVD risk may be related to the role 
of VitD on cardiovascular physiology 481, through several mechanisms that include, a 
negative regulation of the RAAS, direct effect on calcium flow and cardiac myocyte 
growth, regulation of vascular calcification, maintenance of endothelial function, and 
anti-inflammatory and immunomodulatory actions.  
An inadequate VitD status has been associated with hypertension 493-496. 
Hypovitaminosis D has also been associated with type 2 diabetes risk 497-499; several 
meta-analyses also supported this association 500-504. Additionaly, a negative 
association of 25(OH)D levels with all-cause and CVD mortality has been also 
suggested 505-508.  
According to several meta-analyses a negative association was found between 
25(OH)D levels and MetS 502, 509. This association has been documented in both cross-
sectional studies 171, 510-516 and in prospective studies 517-521.A recent meta-analysis 509, 
including 16 cross-sectional studies, found a MetS OR of 0.87 (95% CI 0.83, 0.92) for 
a 25 nmol/L increment in blood 25(OH)D levels.  
The association of 25(OH)D levels with WC 510, 513, 516 and its MetS component 171, 511, 
512, 514, 515 is well documented. Also, several studies reported an association with 
triglycerides levels 513, 516 and their respective MetS component 171, 511, 512, 514, 515. The 
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associations of 25(OH)D with BP 510, 513, 516 and its MetS component 171, 512, 514, 515 as 
well as with glycemia 513, 516 and its component 171, 511, 512, 515 have also been reported. 
Less frequently the association with HDL cholesterol 510, 513, 516 and its component 171, 
515 has been found. 
In addition, 25(OH)D level are positively associated with insulin sensitivity 522 and 
hypovitaminosis may have a negative impact on beta cell function 523.                                                                                                                    
The association of parathyroid hormone (PTH), a hormone with a close regulatory 
relationship with VitD, with CVD risk, has been the subject of some controversy 524, 
525. A meta-analysis on the subject, including 12 studies 526 reported a positive 
association of PTH serum level with total CVD events (pooled HR 1.45; 95% CI 1.24, 
1.71). However, the large Atherosclerosis Risk in Communities Study did not show an 
association with any CVD outcome 527. 
According to a recent meta-analysis 528 including 10 studies, which evaluated the 
relationship between PTH serum levels and all-cause and CVD mortality, there was 
an increased all-cause mortality (pooled RR 1.19; 95%CI 1.08, 1.30) in both sexes and 
an increased CVD mortality (pooled RR 1.68; 95% CI 1.05, 2.67) only in men. 
Findings from population-based cross-sectional studies are not concordant 525, with 
some studies finding a positive association between PTH serum levels and MetS 529-
532 while in others no association was shown 512, 514, 519, 533-535. This association was 
more consistent in elderly men 510, morbidly obese individuals 530 and primary 
hiperparathyroidism 531, 532. The association of PTH with MetS may be explained 
mainly by the associations with the WC 510, 530, BP 536, glycaemia and HDL cholesterol 
risk factors included in the MetS definition 525. 
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5.2. Thyroid function and autoimmunity  
The thyroid is an important endocrine organ responsible for the production of thyroid 
hormones, triiodothyronine (T3) and thyroxine (T4), both having extensive metabolic 
actions. Thyroid dysfunction is a frequent pathology and may take two forms, 
hypothyroidism and hyperthyroidism, signifying a decrease or increase hormone 
production, respectively. Within each type of dysfunction, we can still consider overt 
and subclinical forms 537. 
In Europe, and according to a recent meta-analysis 537, the prevalence of thyroid 
dysfunction was 3.82%. In addition, the prevalence of hypothyroidism and 
hyperthyroidism was 3.05% and 0.75%, respectively. According to the same study, 
subclinical forms of thyroid dysfunction predominated (85.2%) compared to overt 
forms. Moreover, a high prevalence of undiagnosed dysfunction (4.94% and 1.72% 
for hypothyroidism and hyperthyroidism, respectively) was found.  
The information available in Portugal on thyroid dysfunction is scarce, namely with 
regard to the national prevalence of hypothyroidism and hyperthyroidism.  
Iodine deficiency is the leading cause of thyroid disorders, namely goiter and 
hypothyroidism in regions of the globe with inadequate intake of iodine 538.  In regions 
with sufficient iodine intake, thyroid autoimmune disorders play a greater role in the 
etiology of thyroid dysfunction. Among thyroid autoimmune disorders, Hashimoto 
thyroiditis, also known as chronic autoimmune thyroiditis (AIT), stands out for its 
higher prevalence. AIT is still the main cause of hypothyroidism in iodine-sufficient 
areas 538. AIT, as the name implies, results from a chronic inflammatory process 
involving autoimmune mechanisms that translate into lymphocytic infiltration and 
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fibrosis of the gland and the presence of thyroglobulin antibodies (TgAb) and/or 
thyroid peroxidase antibodies (TPOAb) in the blood of most patients 539. As for thyroid 
dysfunction, AIT is poorly studied in Portugal. 
Thyroid hormones have important effects on the cardiovascular system 540 and CVD 
risk, and mortality may be increased in hypothyroidism 541, 542. Low and low-normal 
thyroid function 543 may also increase the risk of type 2 diabetes and excess thyroid 
hormones increase glycaemia 544.  
According to several cross-sectional studies, TSH and thyroid hormones may have an 
association with the prevalence of MetS and its components. Moreover, and although 
the mechanisms remain unclear, the contribution of IR has been consistently reported 
545. A positive association of TSH 546-549 and FT3 550, 551 with IR was documented. In 
contrast, a negative association was reported for FT4 547, 548, 552. 
Several cross-sectional studies conducted in euthyroid individuals 546-550, 552-562, have 
consistently shown a positive association of TSH serum levels with MetS (Table 10). 
In addition, a positive association with the triglycerides component has been 
increasingly reported. Nevertheless, the associations with BP, HDL cholesterol, 
glucose and WC components are less clear.  
Regarding FT4 (Table 11), several studies 547, 548, 550, 552-556, 559-563 have documented a 
negative association with the MetS and its triglycerides and WC components. 
Furthermore, a positive association of FT3 with MetS and its BP, glucose, triglycerides 
and WC components has been reported (Table 12) 550, 551, 553, 554, 559, 560, 562, 564. 
These findings can be explained by the diversity of thyroid hormone effects on energy 
homeostasis, lipid and glucose metabolism and BP 565, 566.  
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The role of AIT in CVD and MetS risk is not yet well defined. AIT may act as an 
independent CVD risk factor through the promotion of chronic inflammation 567, 568.  
According to a recent study 567, the risk for coronary heart disease was increased in 
AIT (HR of 1.44; 95%CI 1.05-1.99). Other studies also found an association with CHD 
568 and stroke 569. Additionaly, a cluster analysis 570 found an association between 
increased TPOAb and homocysteine levels suggesting an adverse effect of these 
alterations in left ventricular systolic function. However, an individual participant data 
analysis of subjects with subclinical hypothyroidism 571, did not show an increased 
CHD risk associated with the presence of TPOAb, suggesting that the cardiovascular 
effects of thyroid autoimmunity can be mediated by thyroid dysfunction. Moreover, a 
20-year follow up study, of the original Whickham study showed no association of 
AIT with coronary heart disease 572. Regarding possible associations between AIT and 
MetS the information is very scarce. In fact, only one study conducted in 
postmenopausal euthyroid women 573 was published on the subject, and no association 
was observed between TgAb and TPOAb levels and MetS. 
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Table 10. Associations between TSH and Metabolic Syndrome and its components 
Country 
Study 
date 
Sample 
size 
Age 
group 
MetS IR BP Gly HDL TG WC 
Roos, 2007 553 1998-2003 1581 a 28-75 - No h No h No h No h Yes (+) h No h 
Pergola, 2008 554 Published 2008 651 p 18-68 No h - No* No* No* No* No* 
Park, 2009 555 2006-2007 949 b PM Yes (+) h No DBP (+)* No * No * Yes (+) * No * 
Garduno-Garcia, 2010 552 Published 2010 2771 c 18-70 - No No * No * No * Yes (+) * No * 
Ruhla, 2010 546 Published 2010 1333 c > 18 Yes (+) h Yes (-) No* No* No* Yes (+) * Yes (+) * o 
Park, 2011 556 2002-2009 5998 c > 18 d Yes (+) i No No No Yes (-) Yes (+) Yes (-) 
Tarcin, 2012 550 Published 2012 211 18-73 e No (+) j - No No No No No 
Waring, 2012 557 1997-1998 1779 c 70-79 Yes (+) k - - - - - - 
Oh, 2013 558 2008-2010 2760 b 18-39 Yes (+) l No Yes (+) No No Yes (+) Yes (+) 
Roef, 2014 559 2002-2004 2315 c 35-55 No l - Yes (+)* No* No* Yes (+)* No* 
Mehran, 2014 547 1997-2004 3755 c ≥ 20 No i Yes (+) No No No Yes (+) No 
Laclaustra, 2015 548 Published 2015 3533 b 20-65 f Yes (+) n Yes (+) Yes (+) No No Yes (+) No 
Kim, 2016 560 2006 13,496 35-65 g No i - No Yes (-) Yes (+) No Yes (-) o 
Park, 2017 549 2007-2014 132,346 b >18 Yes (+) i Yes (+) SBP (+)* Yes (+)* Yes (-)* Yes (+)* Yes (+)* 
Mehran, 2017 561 1997-2004 5,422 c ≥20 - i No No* No* No* Yes (+)* No* 
Wolffenbuttel, 2017 562 2007 26,719 b 18-80 No n - No W:Yes (+) M:Yes (-) Yes (+) No 
 
a Age and gender adjusted; b adjusted for age and other variables (excluding gender); c adjusted for age, gender and other variables; d included suclinical forms; e only 
obese participants; f only men; g total T3 and T4 levels, h ATP III (2001); i JIS modified; j AHA/NHLBI (2005); k ATP III modified; l IDF; m specific Japanese 
definition 504; n JIS; o WC replaced by BMI; p BMI≥ Kg/m2. 
W, women (only); M, men (only); PM, postmenopausal women; MetS, metabolic syndrome; IR, insulin resistance; BP, Blood pressure; Gly, Glycaemia; HDL, HDL 
cholesterol; TG, triglycerides; WC, waist circumference; DBP, diastolic blood pressure; SBP, systolic blood pressure. 
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Table 11. Associations between FT4 and Metabolic Syndrome and its components 
Study 
Study 
date 
Sample 
size 
Age 
group 
MetS IR BP Gly HDL TG WC 
Roos, 2007 553 1998-2003 1581 b 28-75 - i Yes (+) No Yes (-) Yes (+) Yes (-) Yes (-) 
Pergola, 2008 554 Published 2008 651 p 18-68 No i - No* No* No* No* No* 
Park, 2009 555 2006-2007 949 c PM No i       
Kim, 2009 563 2005-2006 44, 196 a 27-70 No k - Yes (+) Yes (+) Yes (-) Yes  (+) Yes (-) 
Garduno-Garcia, 2010 552 Published 2010 2771 d 18-70 - i Yes (-) No * No * Yes (+) * No * No * 
Park, 2011 556 2002-2009 5998 d > 18 e No j No DBP (+) No Yes (+) Yes (-) Yes (+) 
Tarcin, 2012 550 Published 2012 211 a 18-73 f Yes (+) k No Yes (+) Yes (+) No No No 
Roef, 2014 559 2002-2004 2315 d 35-55 Yes (-) m - No* No* No* Yes (-)* Yes (-)* 
Mehran, 2014 547 1997-2004 3755 d ≥ 20 Yes (-) j Yes (-) Yes (+) No Yes (+) Yes (-) Yes ( -) 
Laclaustra, 2015 548 Published 2015 3533 c 20-65 g Yes (-) o Yes (-) No No No Yes (-) No 
Kim, 2016 560 2006 13,496 35-65 h No j - Yes (+) No No No No p 
Mehran, 2017 561 1997-2004 5,422 d ≥20 - j No DBP (-) Yes (+) No Yes (-) Yes (-) 
Wolffenbuttel, 2017 562 2007 26719 c 18-80 Yes (-) o - W:SBP (+) M:Yes (-) M:Yes (+) Yes (-) Yes (-) 
 
* Continuos variables (not MetS components). 
a Age adjusted ; b Age and gender adjusted; c adjusted for age and other variables (excluding gender); d adjusted for age, gender and other variables; e included 
suclinical forms; f only obese participants; g only men; h total T3 and T4 levels, i ATP III (2001); j JIS modified; k AHA/NHLBI (2005); l ATP III modified; m IDF; n 
specific Japanese definition 504; o JIS; p WC replaced by BMI; q BMI≥ Kg/m2.  
W, women (only); M, men (only); PM, postmenopausal women; MetS, metabolic syndrome; IR, insulin resistance; BP, Blood pressure; Gly, Glycaemia; HDL, HDL 
cholesterol; TG, triglycerides; WC, waist circumference; DBP, diastolic blood pressure; SBP, systolic blood pressure. 
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Table 12. Associations between FT3 and Metabolic Syndrome and its components 
Study 
Study 
date 
Sample 
size 
Age 
group 
MetS IR BP Gly HDL TG WC 
Roos, 2007 553 1998-2003 1581 a 28-75 - No No No No Yes (-) g No 
Pergola, 2008 554 Published 2008 651 m 18-68 No g - No* No* No* No* No* 
Tarcin, 2012 550 Published 2012 211  18-73 e No h No No No No No No 
Roef, 2014 559 2002-2004 2315 c 35-55 n Yes (+) n - Yes (+)* No* Yes (-)* Yes (+)* Yes (+)* 
Kim, 2016 560 2006 13,496  35-65 f Yes (+) j - Yes (+) Yes (+) Yes (-) Yes (+) Yes (+) l 
Kim, 2017 551 2006-2012 12,037  35-65 Yes (+) Yes (+) Yes (+)* Gli (+)* Yes (+)* Yes (+)* - 
Ferrannini, 2017 564 2002-2004 940  30-60 - Yes (+) Yes (+)* No* Yes (-)* Yes (+)* - 
Wolffenbuttel, 2017 562 2007 26719 b 18-80 Yes (+) k - Yes (+) Yes (+) Yes (-) Yes (+) Yes (+) 
 
* Continuos variables (not MetS components). 
aage and gender adjusted; b adjusted for age and other variables (excluding gender); c adjusted for age, gender and other variables; d included suclinical forms; e only 
obese participants; f total T3 and T4 levels, g ATP III (2001); h AHA/NHLBI (2005); i specific Japanese definition 504; j JIS modified; k JIS; l WC replaced by BMI; m 
BMI≥ Kg/m2; n IDF. 
MetS, metabolic syndrome; IR, insulin resistance; BP, Blood pressure; Gly, Glycaemia; HDL, HDL cholesterol; TG, triglycerides; WC, waist circumference; DBP, 
diastolic blood pressure; SBP, systolic blood pressure. 
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II. Objectives 
 
The main objective of this thesis was to evaluate the prevalence of MetS and its 
determinants in Portugal, having a specific focus on the influence of obesity and 
endocrine pathology, namely hypovitaminosis D and thyroid dysfunction and 
autoimmunity. In order to carry out this main objective, several specific objectives 
were set: 
1. To assess which adiposity measure better perform in the identification of MetS 
in a sample of Portuguese adults and to estimate the cut-off values for these 
adiposity anthropometric measures (Paper 1).  
2. To assess the prevalence of MetS and its determinants in the overall and 
administrative regions of the Portuguese mainland, according to the 2009 JIS 
definition, using the WC cut-off points that that best fitted the Portuguese 
population (Paper 2). 
3. To evaluate the prevalence of hypovitaminosis D and its determinants as well 
as PTH serum levels determinants and associations of the 25(OH)D and PTH 
serum levels with MetS and its individual components in a sample of the 
Portuguese mainland population (Paper 3).  
4. To evaluate in a sample of the Portuguese population, the prevalence of thyroid 
dysfunction and antibody positivity and to assess the associations of thyroid-
stimulating hormone (TSH), thyroid hormones and thyroid antibodies with the 
MetS, its components (Paper 4).  
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III. General Methodology 
 
1. PORMETS study 
PORMETS is a national cross-sectional study. A sample of adults registered at primary 
health care centres throughout mainland Portugal was selected. In each of the eighteen 
Portuguese mainland administrative regions (districts), two health care centres were 
included, one in the district’s capital and the other representative of a non-urban area. 
Apart from the district of Setubal that only included one centre, all the others included 
two, for a total of 35 health care centres.  
 
1.1. Participants 
At each health care centre, participants were randomly selected from the general 
practitioner’s patient lists, and 120 participants were recruited, with an inclusion 
criterion of being aged 18 or older. A total of 4105 participants was evaluated, and 
information was collected from February 2007 to July 2009. Ten participants were 
excluded from the data analysis because they were pregnant at the time of the 
interview, resulting in 4095 remaining participants.  
After excluding participants who had missing information on the MetS features, for all 
the three operational definitions (the ATP III 4, 5, IDF 10, 11, and JIS 1) considered, 
the analysis to assess the prevalence of MetS and its determinants in the overall and 
administrative regions of the Portuguese mainland, included 4004 participants, 2309 
women and 1695 men.  
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After additional exclusion of participants with missing information on height, weight, 
WC, and HC, the remaining 3,956 participants (2,287 women and 1,669 men) were 
included in the data analysis to assess which adiposity measure performed better in 
identifying MetS and to estimate the cut-off values for these anthropometric measures.  
A sub-sample including 500 participants (286 women and 214 men) was randomly 
selected from the initial PORMETS sample. This sub-sample size was calculated 
considering a margin of error of 5%, confidence level of 95% and response distribution 
of 50% for the proportion of participants with MetS, 25(OH)D levels below 30 ng/mL 
(75 nmol/L), thyroid dysfunction and thyroid antibody positivity. The sub-sample was 
used to evaluate the prevalence of hypovitaminosis D and its determinants as well as 
PTH serum levels determinants and associations of the 25(OH)D and PTH serum 
levels with MetS and its individual components. The comparison between the selected 
(500) and non-selected participants (3595) did not show significant differences, except 
for systolic BP (p=0.038) and for insulin serum levels (p=0.040), although, the 
magnitude of the differences between estimates were low (Table 13).  
This sub-sample of 500 participants, was also used to evaluate the prevalence of 
thyroid dysfunction and antibody positivity and to assess the associations of TSH, 
thyroid hormones and thyroid antibodies with the MetS, its components, and other 
possible determinants. After exclusion of 14 participants with missing values for TSH, 
486 participants (281 women and 205 men) remained. Participants with previously 
diagnosed hypothyroidism (n=7) and under treatment with L-thyroxine were included 
in the evaluation of the prevalence of thyroid dysfunction but excluded for the 
remaining analyzes, to minimize the influence of medication in the results. The 
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comparison between the selected (486) and non-selected (3595) participants did not 
show significant differences (p˂0.05), except for insulin serum levels (p=0.046), but 
again without relevant differences between estimates. 
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Table 13. Comparison between the 500 randomly selected and non-selected 
participants 
Variables 
Non-selected 
participants 
Selected 
participants 
p value 
Gender [(n (%)] 
Women 2069 (57.6) 286 (57.2)  
Men 1526 (42.4) 214 (42.8) 0.881 
Age (years) [median (P25, P75)] 54 (41, 66) 53 (41, 67) 0.856 
Education level (years) [median (P25, P75)] 4 (4, 9) 6 (4, 9) 0.224 
Alcohol intake  
[(n (%)] 
No 1621 (45.2) 229 (45.9)  
Yes 1969 (54.8) 270 (54.1) 0.756 
Smoking habits  
[(n (%)] 
No 2487 (69.3) 359 (71.8)  
Yes 1104 (30.7) 141 (28.2) 0.247 
Physical exercise  
[(n (%)] 
No 2592 (73.1) 352 (71.7)  
Yes 954 (26.9) 139 (28.3) 0.511 
UV exposure  
[(n (%)] 
Lower 1971 (55.9) 283 (56.6)  
Higher 1555 (44.1) 217 (43.4) 0.768 
Weight (Kg) [median (P25, P75)] 71.0 (62.2, 80.8) 71.0 (61.0, 80.5) 0.704 
Height (cm) [median (P25, P75)] 
162.0 (156.0, 
169.0) 
162.0 (155.0, 
169.0) 
0.745 
BMI (Kg/m2) [median (P25, P75)] 27.0 (24.0, 30.0) 27.1 (24.1, 29.8) 0.813 
WC (cm) [median (P25, P75)] 93.5 (85.0, 101.5) 94.0 (86.0, 102.0) 0.399 
Systolic BP (mmHg) [median (P25, P75)] 130 (117, 145) 131 (119, 147) 0.038 
Diastolic BP (mmHg) [median (P25, P75)] 79 (70, 86) 80 (70, 87) 0.073 
Glucose (mg/dL) [median (P25, P75)] 85 (77, 97) 85 (77, 97) 0.947 
Insulin (µU/mL) [median (P25, P75)] 7.6 (5.1, 11.4) 8.1 (5.3, 12.2) 0.040 
HOMA [median (P25, P75)] 1.6 (1.0, 2.6) 1.7 (1.1, 2.9) 0.119 
hs-CRP (mg/L) [median (P25, P75)] 0.15 (0.07, 0.36) 0.16 (0.08, 0.39) 0.626 
Cholesterol (mg/dL) [median (P25, P75)] 206 (179, 234) 205 (180, 233) 0.611 
Triglycerides (mg/dL) [median (P25, P75)] 106 (78, 147) 104 (76, 143) 0.242 
HDL cholesterol (mg/dL) [median (P25, P75)] 47 (39, 55) 47 (39, 55) 0.553 
MetS [(n (%)] 
No 2086 (59.8) 307 (61.6)  
Yes 1403 (40.2) 191 (38.4) 0.428 
BP component [(n (%)] 
No 1352 (38.4) 177 (35.5)  
Yes 2172 (61.6) 322 (64.5) 0.212 
WC component [(n (%)] 
No 1812 (51.6) 253 (50.6)  
Yes 1702 (48.4) 247 (49.4) 0.686 
Glucose component [(n (%)] 
No 2655 (76.4) 382 (77.3)  
Yes 822 (23.6) 112 (22.7) 0.635 
HDL-C component [(n (%)] 
No 1566 (44.7) 224 (44.8)  
Yes 1935 (55.3) 276 (55.2) 0.977 
TG component [(n (%)] 
No 2615 (74.9) 383 (76.6)  
Yes 878 (25.1) 117 (23.4) 0.401 
UV, ultraviolet; BMI, body mass index; WC, waist circumference; BP, blood pressure; HOMA, 
homeostatic model assessment; hs-CRP, high sensitivity C-reactive protein; HDL, high density 
lipoprotein; MetS, metabolic syndrome; TG, triglycerides. 
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1.2. Methods 
All of the Portuguese Regional Health Administrations, the Ethics Committee of the 
São João Hospital E.P.E. (authorized in 27th February 2007) and the Portuguese Data 
Protection Authority (authorization number: CNPD 1053/2007) approved PORMETS. 
The coordinator of each health care centre also provided authorization and all 
participants provided written informed consent. 
A trained nurse administered a structured questionnaire with only closed-ended 
questions; information was collected regarding personal medical history and socio-
demographic and behavioural characteristics. A participant was considered a current 
smoker if he/she smoked daily or occasionally, a former smoker those who stopped 
smoking for at least six months, and a never smoker if the participant had never 
smoked 574. Regarding alcohol intake, the participants were categorized as occasional 
drinkers if he/she had less than an alcoholic drink per day, daily drinker if he/she 
consumed, at least one drink per day, and a non-drinker if he/she did not consume any 
alcoholic beverages. Regular physical exercise was considered when the participant 
was engaged in some leisure-time physical activity performed on a repeated basis, 
spending at least 30 min a week. Four meteorological seasons were considered 575. 
Participants evaluated in the June-November period (winter and fall) and December-
May period (winter and spring) were classified, respectively, as “higher” and “lower” 
ultraviolet radiation exposure, according to a previous national study that showed 
25(OH)D serum levels higher in summer and fall and lower in winter and spring 473. 
Portuguese regions were classified as North, Center, Lisbon, Alentejo and Algarve 
according to the NUTS2 level statistical regions of the European Union. 
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Anthropometrics measures were taken by the same nurse that applied the 
questionnaire, namely weight, height, WC and HC. Body weight was measured to the 
nearest 0.1 kg using a digital scale, and height was measured to the nearest centimetre 
in the standing position using a wall stadiometer. The WC was measured midway 
between the lower limit of the rib cage and the iliac crest and the HC was measured as 
the maximum circumference of the buttocks. BMI was calculated as the weight in 
kilogrammes divided by the square height in metres. The WHtR was calculated as the 
WC divided by the height, and the WHR, as the WC divided by the HC, all in 
centimeters. BAI 59 was calculated using the formula BAI = (HC cm) / (Height m)1.5) 
– 18.  
BP was measured on a single occasion using a standard mercury sphygmomanometer 
with the cuff on the upper right arm after a 10-min rest. Two BP readings were taken, 
and the mean of the two readings was calculated. If the difference between the two 
measures was larger than 5 mmHg for systolic or diastolic BP, a third measurement 
was acquired and the mean of the two closest values was registered. 
A fasting venous blood sample was collected in each health care center and frozen 
samples were stored at – 80º C. All blood sampling analyses were performed centrally 
at the Department of Clinical Pathology, Centro Hospitalar São João, Porto, Portugal. 
A chemiluminescent immunoassay using a Liaison automated analyzer (Diasorin 
Iberia, Madrid, Spain) was used to measure 25(OH)D. Biointact PTH and insulin were 
determined by an electro-chemiluminescent immunoassay using a Cobas e411 
automated analyzer (Roche, Amadora, Lisboa, Portugal). High sensitivity C-reactive 
protein (hs-CRP) was measured using a particle-enhanced immunonephelometric 
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assay on a BNII laser nephelometer. (Siemens Healthcare, Amadora, Lisboa, 
Portugal). 
All other parameters [glucose, total cholesterol, triglycerides, HDL cholesterol, 
calcium, phosphorus, albumin, creatinine, TSH, free triiodothyronine (FT3), free 
thyroxine (FT4), TPOAb and TgAb] were measured using conventional methods with 
an Olympus AU5400 automated clinical chemistry analyser (Beckman-
Coulter,Oeiras, Lisboa, Portugal). All participants with triglycerides levels below 
400 mg/dl had their LDL cholesterol level computed. This value was estimated by 
subtracting the HDL cholesterol value plus 20% of the triglycerides from the total 
cholesterol 576. IR was estimated by the HOMA, from fasting glucose (mmol/L) and 
insulin (μUI/mL), as the product of the two divided by 22.5 577. 
Participants were classified according to the WHO criteria 578: underweight, normal 
range, pre-obese and obese categories, which are defined as BMI ˂ 18.5 kg/m2, ≥18.5 
to ˂25 kg/m2, ≥ 25 to < 30 kg/m2 and  30 kg/m2, respectively.  
Three operational definitions of MetS were used: the ATP III 4,5, IDF 10, 11, and JIS 1. 
MetS was considered present by ATP III if at least three (any) of the following 
characteristics were present: fasting glucose ≥110 mg/dL; BP ≥ 130/85 mmHg; 
triglycerides ≥150 mg/dL; HDL cholesterol < 40 mg/dL in women and <30 mg/dL in 
men; WC > 88 cm in women and >102 cm in men. Participants who reported the use 
of antihypertensive or antidiabetic therapy were also considered as having the 
corresponding MetS feature by the ATP III classification. The considered IDF 
definition was WC ≥ 80 cm in women and ≥94 cm in men and the presence of at least 
two of the following characteristics: fasting glucose ≥100 mg/dL or previously 
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diagnosed type 2 diabetes; BP ≥ 130/85 mmHg or antihypertensive medication; 
triglycerides ≥150 mg/dL or current treatment for this lipid abnormality; HDL 
cholesterol < 40 mg/dL in women and <30 mg/dL in men or current treatment for this 
lipid abnormality. Finally, the JIS defined MetS as the presence of at least three (any) 
of the following characteristics: fasting glucose ≥100 mg/dL or antidiabetic treatment; 
BP ≥ 130/85 mmHg or antihypertensive medication; triglycerides ≥150 mg/dL or 
specific treatment for this lipid abnormality; HDL cholesterol < 40 mg/dL in women 
and <30 mg/dL in men or specific treatment for this lipid abnormality; WC ≥ 88 cm in 
women and ≥102 cm in men (“European” cut off points). 
Elevated cardiometabolic risk was considered when two or more of the four criteria of 
MetS were present, excluding the WC component 46, 49. 
VitD adequacy was classified according to the Institute of Medicine (IOM) 
recommended cut-off values for 25(OH)D levels 471: deficiency below 12 ng/mL (30 
nmol/L); inadequacy  12 and < 20 ng/mL ( 30 and < 50 nmol/L) and sufficiency  
20 ng/mL ( 50 nmol/L).  
Hyper- and hypoparathyroidism were defined as PTH levels above and below the 
standard laboratory reference range (10-65 pg/mL), respectively, and a “blunted PTH 
response” was defined as a PTH level within the reference range in the presence of 
25(OH)D  12 ng/mL (30 nmol/L) 579. 
Euthyroidism was defined by normal TSH (0.4 to 3.99 mU/L), FT4 (0.70 to 1.48 
ng/dL) and FT3 (1.71 to 3.71 pg/mL) serum levels. Overt primary hypothyroidism was 
defined by a serum TSH level ≥ 4 mU/L and FT4 serum levels below the lower range. 
Subclinical hypothyroidism (SCH) was defined as a state of increased serum TSH 
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levels, with circulating thyroid hormone concentrations within the reference range. 
SCH was divided into two categories according to TSH levels: mildly increased TSH 
(4.0–10.0 mU/L) and severely increased TSH (>10 mU/L) 580. Overt primary 
hyperthyroidism was defined as serum TSH <0.4 mU/L and serum FT4 and/or FT3 
levels above the normal range. Subclinical hyperthyroidism (SHyper) was defined 
biochemically as serum TSH levels below the reference range, with normal thyroid 
hormone levels. According to its severity, SHyper was divided into two categories 581: 
grade 1, which has low but detectable serum TSH levels (0.1–0.39 mU/l), and grade 
2, which has undetectable serum TSH levels (<0.1 mIU/l). 
Positivity for TPOAb and TgAb was set to values greater than or equal to 5.61 and 
4.11 IU/mL, respectively. 
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IV. Results 
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V. Overall Discussion 
 
The present thesis intended to study the MetS and its determinants in Portugal. To 
reach these objectives, we assessed the cutoff points that best estimated the MetS 
associated risk for CVD and diabetes in a representative sample of the Portuguese 
population and the prevalence of MetS itself according to the main definitions, using 
previously estimated cutoff points (Paper 1). Secondly, the prevalence of MetS was 
assessed according to the most consensual definition (JIS) and according to cut-off 
points proposed by the previous study (“European”); several possible determinants of 
the MetS were also evaluated in the same sample of the Portuguese population (Paper 
2). At a later stage, we were able to evaluate other possible determinants of MetS, in a 
subsample, with a focus on the most frequent endocrine pathology and in particular on 
VitD deficiency (Paper 3) and thyroid dysfunction and autoimmunity (Paper 4). 
To meet the first objective, the cut-off points that better diagnosed the cardiometabolic 
risk for several adiposity measures were estimated.  
According to our results, the correlations of elevated cardiometabolic risk, defined by 
the presence of two or more of the four JIS criteria excluding the WC component 46, 
49, with the different adiposity measures considered, were higher for WHtR, WC and 
BAI than for BMI in both sexes. Similar results were obtained for the AUC. These 
findings are in agreement with previous studies showing a slight advantage of WC and 
WHtR over BMI in estimating the risk of type 2 diabetes 28, 29, 30, 31 and CVD   25, 47-55, 
582. The best performance of these AO measures may be related to the greater 
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association with VAT 46, 583. VAT may have a stronger impact than total body fat and 
SAT on IR 38-43, 337, diabetes 336 and CVD 335 risk. 
The stronger association of BAI with cardiometabolic risk when compared to BMI is 
not supported by the majority of the studies on the subject. 46, 62-65. In fact, BAI was 
not designed to estimate diabetes and CVD risk 59As it was initially proposed as an 
alternative to BMI for the estimation of body fat mass and percentage of fat, being 
validated in two specific ethnic groups, Mexican and African Americans. These 
participants were relatively young (mean age of 35 years) and there was a women 
predominance. Thus, the differences found regarding the association of BAI with 
cardiometabolic risk may be related in part to the variety of factors such as ethnicity, 
age, sex and diabetes and CVD frequency among the populations studied.   
The analysis of the association of the various adiposity measures with cardiometabolic 
risk showed some gender differences. WC, WHtR and BAI disclosed a higher 
correlation and AUC in women than in men, as previously reported 583, 584.  
In addition, women presented lower cut-off points for weight, BMI, WC, WHtR and 
WHR and higher values for HC and BAI, than men.  HC primarily reflects lower 
abdominal fat deposits of the SAT, which are associated with a lower cardiometabolic 
risk. In fact, this type of deposits has a negative association with the risk of MetS in 
both men and women 585. The storage capacity in the SAT may operate up to a certain 
limit as a protective mechanism for VAT deposition 586, 587. Given that women 
generally have higher mean values of HC 588, it may be assumed that the fat storage 
capacity in the SAT may be higher in women than in men. Since BAI is derived from 
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HC, it is reasonable to assume that higher cut-offs in women than in men may reflect 
HC's influence on the index. 
The lower BMI cut-off points found in women are difficult to explain. According to 
the literature, the BMI related risk of diabetes starts early in men. In fact, at the time 
of diagnosis, men present lower BMI values than women 419, 589, 590. In addition, the 
CVD risk is similar, given the BMI, in both sexes 591. 
With regard to AO adiposity measures (WC, WHR and WHtR) our findings are in line 
with the epidemiological data on obesity gender specificities. Several studies showed, 
that the type 2 diabetes and CVD risk associated with AO measures, namely WC, can 
increase in women at lower cut-off points 583, 584, 592-596. In fact, the Nurses' Health 
Study showed a RR of type 2 diabetes, for the 90th versus the 10th percentile (92 and 
67 cm, respectively) of 5.1 (95%CI 2.9, 8.9) 595. According to a British study on CHD 
risk in women, a HR of 3.0 (95%CI 1.8, 4.9) was found for WC of 81 cm or higher 
(versus WC lower than 70 cm) 594. In addition, according to a study that compared 
gender WC differences and CHD risk 596, which included 51,529 men of the Health 
Professionals Follow-up Study and 121,700 women of the Nurses’ Health Study 
cohort, lower WC thresholds for CHD risk were found in women than in men (71 cm 
and 84 cm, respectively). 
These differences have been related to the gender dynamics of the fat deposits 
distribution 586, 597, 598. The percentage of body fat is higher in women for the same 
BMI 599. Moreover, men generally accumulate more fat in the upper body and women 
in the lower body 46. In fact, for a similar total body fat mass, men present higher WC 
than women; on the other hand women present higher fat mass to a similar WC 78. 
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Furthermore, for a given WC, both men and women present similar VAT area. 
Nevertheless, the correlation of WC with VAT may be higher in women than men 
(r=0.87 versus r=0.77), and the metabolic effects of VAT may be increased in women 
600. VAT may be more sensitive to the anti-lipolytic effects of insulin in women 601, 602. 
Thus, for the same degree of IR, lipolysis may be more active in women than in men. 
In fact, and according to the number of MetS components present, women have less 
VAT than men for any number of components 585. In addition, the association of VAT 
with the risk of MetS may be stronger in women [OR of 2.13 (95%CI 1.59, 2.84)] than 
in men [OR of 1.38 (95%CI 1.02, 1.85)] 585.   
According to our results, WC and WHR cut-off points showed greater sensitivity in 
both sexes and WHtR also worked well in women. BMI, WHtR and BAI cut-off points 
showed greater specificity in both sexes, especially in men. Despite the high 
sensitivity, WHR presented a low specificity; in addition, it presented greater accuracy 
in men than in women 603. 
Overall, BMI, WC, WHtR and BAI were the adiposity measures with higher accuracy 
in both sexes. Among these measures, WHtR showed a slight advantage over WC in 
both sexes. On the other hand, the comparison of BMI with WC showed greater WC 
sensitivity and BMI specificity in both sexes, as well as greater accuracy and negative 
predictive value (NPV) for WC and a greater negative and positive likelihood ratio 
(LR) for BMI, in men. The performance of our estimated cut-off points, namely in 
terms of sensitivity and specificity, compared with other studies that used similar 
methodologies, revealed some differences 583, 584, 592.  
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Taking into account that WC is the most used adipose indicator in the different 
definitions of MetS and that the differences in diagnosis performance of 
cardiometabolic risk are not relevant compared to WHtR, our results do not support 
the substitution of WC by WHtR in the definition of MetS. Nevertheless, taking into 
account the good results of the WHtR, its use can be suggested in benchmarking 
studies of populations with diverse ethnic characteristics, because this indicator can 
attenuate the influence of height in the assessment of abdominal adiposity 57, 604.   
According to our results, the estimated cut-off points for WC were 89.0 cm in women 
and 93.5 cm in men. Compared with the cut-off points proposed by the National 
Institute of Health (88 cm in women and 102 cm in men) 83, obtained in populations 
of European origin, our estimates are lower in men. In addition, according to the sex-
specific WC cut-off points proposed by WHO 80, 92 for the identification of high (80 
cm for women and 94 cm for men) and very high (88 cm for women and 102 cm for 
men) AO related metabolic risk, our thresholds are similar to those set for high risk in 
men and very high risk in women. This data suggest, that in women, the 
cardiometabolic risk associated with WC may start with higher values compared to 
other populations. 
The comparison of the estimated national cut-off points with the results of other 
worldwide studies 94, 95 is not conclusive considering the dispersion of reported cut-off 
points (65.5 to 101.2 cm for women and 72.5 to 103.0 cm for men). However, similar 
cut points were found in two Spanish studies 137,  605 (88.5 to 89.5 cm in women and 
94.5 cm in men), probably reflecting the geographical proximity and the genetic and 
epigenetic similarities with the Portuguese population.  
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According to the cut-off points proposed by the WHO 92 to define the high and very 
high risk categories for AO that coincide with the “Europid” and “European” cut-off 
points of the JIS definition, respectively, the prevalence of AO in our sample was 
81.0% and 60.7% in women and 62.1% and 32.7% in men. These results were slightly 
higher than those found in other national studies 97, 99, 108.  
Taking into account that the WC cut-off point for the diagnosis of increased 
cardiometabolic risk in women was very close to 88.0 cm and to avoid over-diagnosis, 
we considered the use of European cut-off points more appropriate. In fact, according 
to the “Europid” cut-offs, most women (81%) would have the WC component of MetS. 
Thus, we propose, according to the current international recommendations, the use of 
JIS criteria for the definition of MetS in the Portuguese population using "European" 
cut-off points. 
According to our results, men with a WC of 94.0 cm or more, which meet WHO 
criteria for high risk AO 92 should also receive increased attention.  
According to JIS criteria and using the European cut-off points, the age-adjusted 
prevalence of MetS in this sample was 45.7%, 39.8% and 43.1%, in women, men and 
both sexes, respectively. The prevalence was significantly higher in women. The high 
prevalence of MetS found in our sample is supported by other Portuguese studies 132, 
134, 135. Compared to our results (MetS crude prevalence of 32.7%, 40.0% and 45.9%, 
according to ATP III, JIS and IDF definitions, respectively), lower prevalence of MetS 
was found in the EPIPorto study 132 (24.0%, 27.6% and 41.9% according to the ATP 
III, JIS and IDF definitions, respectively), conducted in the city of Porto during 1999-
2003, and including a younger population (mean age of 52.5 years) recruited with a 
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different methodology. On the contrary, the VALSIM study 133, 135, carried out in 
mainland Portugal and the islands of Madeira and the Azores, between 2006 and 2007, 
with different selection criteria and older population (mean age of 58.1 years), showed 
a higher prevalence (28.4%, 69.4% and 65.5%, according to the ATP III, JIS and IDF 
definitions, respectively). Another national study, the PREVADIAB study conducted 
from 2008 to 2009, with a different methodological approach, showed a crude 
prevalence of 41.5% by IDF criteria 134. The Portuguese prevalence of MetS is higher 
than in most European countries, according to studies conducted in Northern 150-159, 
Western 160-172, Southern 136-149 and Eastern 110, 173-190 Europe. The national prevalence 
of MetS is also higher than in the USA 193-195, 197, 198. Compared to other world regions, 
including Asia-Pacific 205-224, Middle East 225-241, Africa 242-251 and America 196-204, 
Portugal also presents a high prevalence.  
Several other national studies 132, 133 have shown a higher prevalence of MetS in 
women. Although most European studies showed a higher prevalence in men, some 
studies have also shown a higher prevalence among women 174, 189, 190, 279, 288, 606. The 
higher prevalence of WC and HDL cholesterol components of the MetS in women 
compared with men may help to explain our results. These two components of the 
MetS are the only ones that present different thresholds according to gender. 
Regarding the WC component and as mentioned above, it is well documented that 
cardiometabolic risk may be initiated for lower WC cut-off points in women 583, 584, 592-
596. Nevertheless, the established cut-off points may not be suitable for different 
populations, as exemplified by our study. Unlike in men where HDL cholesterol levels 
are stable throughout their life, in women these levels decrease with age. 607, 608. Even 
so, women maintain HDL cholesterol levels about 10 mg / dL higher than men for all 
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age groups. Taking into account that the impact of low HDL cholesterol levels on 
CVD, may be higher in women 609-612, their thresholds for the HDL cholesterol 
component have been adapted 613, 614. Nonetheless, the cut-off points for HDL-
cholesterol may vary according to populations 615. Additionaly, given the high 
prevalence of AO in women and its influence on HDL levels 616, it is likely that the 
higher prevalence of MetS in women is mainly due to obesity.  
Comparison of MetS prevalence by JIS criteria with earlier MetS definitions showed 
a lower prevalence according to the ATP III definition and a higher prevalence 
according to IDF definition. These differences were confirmed by previous national 
studies 132, 134, 135.  
The discrepancy of these results is justified by the differences in the definition of the 
MetS components. Thus, according to ATP III the threshold for glycemia is higher 
than in the other definitions and subjects medicated for risk factors are not included. 
In the case of the IDF definition in addition to the requirement for the AO component, 
the cut-off points of this component are lower than in all other definitions. 
According to our data the prevalence of the BP, AO and glucose components was 
64.3%, 51.0% and 24.9%, respectively. Atherogenic dyslipidemia also played an 
important role in the prevalence of the MetS (29.4% for triglycerides and 56.5% for 
HDL cholesterol components, respectively). 
The higher prevalence of the BP component of the MetS in comparison with the other 
components of the MetS can be explained by the high national prevalence of 
hypertension (42.2%) 130, 617, 618, and because the systolic and diastolic thresholds for 
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the Mets BP component are lower than those used in the definition of hypertension 
(respectively 140 and 90 mmHg) 619, 620. 
The high prevalence of the WC component of MetS, only surpassed by the BP 
component, is also explained by the high national prevalence of obesity 99-102, 107. 
However, the estimated prevalence of AO (European thresholds) in the PORMETS 
study was higher than in other Portuguese studies 97, 99, 108. In two of them, the same 
WC measurement methodology was used but they were carried out before 2007, in the 
periods 1999-2003 108 and 2003-2005 97. In addition, another study 99, temporally 
closer (2008-2009), used another methodology for WC measurement (immediately 
above the iliac crest). 
According to our data the glucose component of MetS had the lowest contribution to 
the prevalence of the syndrome, despite the tendency of increase due to the inclusion 
of diabetic individuals in its definition. Moreover, Portugal has one of the highest 
prevalence of diabetes in Europe 131, 621, 622, and there is a national trend for increased 
incidence of diabetes 623, accompanying the overall increase 624. Nevertheless, taking 
into account that, the prevalence of diabetes and impaired fasting glycaemia (fasting 
glycaemia ≥ 110 mg / dL), according to the PREVADIAB study 40, was 11.7% and 
8.2, respectively, a slightly higher value than the sum of the two could be anticipated 
for the glucose component. 
Our study also showed a higher prevalence of the HDL cholesterol component and a 
discretely lower prevalence of the triglycerides component, than that reported in 
previous national MetS prevalence studies 132, 133. Nevertheless, according to a recent 
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national systematic review 625 mean HDL cholesterol and triglycerides levels were 
similar to our results.  
The analysis of the estimates of the age and sex-adjusted prevalence ratio of MetS by 
districts of Portugal mainland showed some differences. “Vila Real” and "Leiria" 
districts had the highest prevalence of MetS and, on the contrary, "Bragança" and 
"Beja" districts presented the lowest prevalence. In addition, participants from non-
urban areas presented a higher prevalence ratio than participants from urban areas. 
Several studies have also found differences between populations living in urban areas 
and those living in non-urban or rural areas. Some of them 257, 258, 262 also showed a 
higher non-urban or rural prevalence. On the contrary, other studies showed a higher 
prevalence in urban populations 208, 252, 256.  
Demographic, ethnic, socio-economic and lifestyle factors may have contributed to the 
differences found in the area of residence and between districts 257, 258, 262, 626. However, 
these factors were addressed in our study and did not explain the differences observed.  
We did not evaluate the participants eating patterns, and therefore the contribution of 
diet cannot be excluded. 
Our results support the association of MetS with increased risk for CVD 381 and type 
2 diabetes 436, and also reinforce the evidence on the presence of IR in subjects with 
MetS 627-629. In addition to the associations found between MetS and serum insulin and 
HOMA-IR values, a greater prevalence of previously diagnosed type 2 diabetes, 
myocardial infarction and stroke, was also found in individuals with MetS.  Despite 
the high prevalence of MetS in Portugal, the CVD mortality rates are relatively low 
when compared with other Western Europe countries 630-632.  
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Our study showed the contribution of several other factors to the increased prevalence 
of MetS. A higher prevalence of MetS was also found in the elderly. This association 
is well documented 606. Indeed, several national 132, 133 and international 139, 155, 198, 387, 
606 studies have shown an increased prevalence of MetS with age.  
Sedentary behaviour was associated with a higher prevalence of MetS. These results 
are also supported by a recent meta-analysis 633. The role of sedentary lifestyle had 
already been highlighted in the AACE statement 9 which had it includedt among the 
risk factors for IRS. In addition to being able to contribute to IR 634 and to the weight 
gain 635, through the reduction of energy consumption, it is also associated with a 
reduction of muscle LPL activity 636 and consequent decrease in muscle uptake of 
triglycerides and serum levels of HDL cholesterol, as well as with increased 
postprandial lipaemia 637, 638. 
In addition, and as expected, an increased prevalence of MetS was found in subjects 
with high BMI. This positive association with BMI probably indicates the contribution 
of adipose tissue to MetS, as discussed above. 
The prevalence of MetS was higher in housewives, retired or unemployed participants. 
The EPIPorto study also found a higher prevalence in housewife and unemployed 
subjects 639. This association with socioeconomically disadvantaged groups has 
already been described 639-642.  
The contribution of VitD deficiency and thyroid pathology, namely dysfunction and 
autoimmunity, for the prevalence of MetS has not been studied in Portugal, despite the 
fact of its likely high frequency and evidence suggesting the possibility that these 
endocrine entities might play an active role in the etiopathogenesis of MetS. 
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According to IOM definition, a high prevalence of VitD deficiency and inadequacy 
(85.6%) was found in our study. Previous national studies also showed high values, 
ranging from 48% to 92.7% 473-476.  
Despite a favourable latitude, the median 25(OH)D levels found in our study (13.8 
ng/mL) were relatively low compared with other European populations 470. Moreover, 
comparing with other worldwide estimates our values were also relatively low 478.  
Several factors may have contributed to the low levels of levels of 25(OH)D found in 
our study. Although cutaneous synthesis is the main source of vitD, dietary sources 
also contribute to the body stores of VitD. In addition to VitD's dietary intake being 
insufficient in Portugal 470, sunlight exposure and UV protection habits may also have 
contributed to the low 25(OH)D levels found in our study. Nevertheless, our study did 
not evaluate the habits of sun exposure and its determinants as well as the use of 
sunscreens. The high prevalence of overweight participants in our sample (42.7 and 
24.2% for pre-obesity and obesity, respectively) may also have contributed to our 
estimates. Food fortification and VitD supplementation health policies related to the 
prevention of hypovitaminosis D in Europe are not the same in all countries, as some 
of them, especially in Northern Europe, have adopted measures to implement VitD 
supplementation and food fortification 470. In other countries, such as Portugal, the 
recommendations are scarce. In fact, there is no national legislation on food 
fortification and VitD supplementation (700-800 IU/day) in adults, it being only 
recommended for elderly populations (> 65 years) and subjects with osteoporosis, 
osteopenia or those with a major risk for osteoporosis 643.  
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VitD and PTH regulate calcium homeostasis and are part of a feedback system in 
which PTH stimulates VitD and in turn, VitD has a PTH inhibitory effect. Thus, PTH 
levels are  
usually increased in the presence of ViD deficiency. It would, therefore, be expected 
to find a significant association between 25(OH) D and PTH serum levels; however, 
no association was found. This lack of association was previously reported 644. There 
may be several justifications for explaining these results. The chemiluminescent 
immunoassay used for the measurement of serum levels of 25(OH)D may have 
underestimated the estimates 645. In addition, prior freezing of serum may have led to 
a decrease in PTH values, as measured by the third generation PTH assay, used in our 
study 646. In contrast, 25(OH)D exhibits great stability under freezing conditions 647. 
The conjugation of artificially lower PTH and 25(OH)D values may have also 
contributed to a high “blunted PTH response” 579 in our study. Although 25(OH)D 
serum levels may be a good marker of VitD supply to target tissues, they may not be 
equally suitable to represent the biological activity of 1α,25(OH)2D, regarding the 
regulation of PTH. Furthermore, the cut-off point considered to define the upper 
reference value of normal serum PTH levels (65 pg/mL) may be inappropriately 
elevated, from a physiological point of view 579, 648. 
According to our data, PTH serum levels presented a significant positive association 
with age and a negative one with the male gender. These results are supported by 
previous studies 649, 650. By contrast, 25(OH)D serum levels showed no association 
with gender or age. 
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Serum levels of PTH and 25(OH)D showed significant positive associations with some 
adiposity measures. Both showed an association with BMI and only PTH had an 
association with WC. The association of PTH with adiposity is well documented 651, 
especially in primary hyperparathyroidism 652. The effect of PTH on the adipose tissue 
may be mediated by an increase in calcium influx in adipocytes and subsequent 
increase in adipose mass, especially VAT 653. Unlike PTH, any role of VitD in the 
pathogenesis of obesity is probably small. Indeed, and according to a bi-directional 
Mendelian randomization analysis, obesity may play a causal role in VitD status 654. 
The lower serum levels of 25(OH)D in obesity, may be explained by several 
mechanisms 655, which include: lower VitD dietary intake, reduced sunbathing habits 
due to a decreased willingness to expose the body, sedentary lifestyle and mobility 
limitations, decreased bioavailability due to sequestration in the adipose tissue and a 
volumetric dilution effect related to greater body weight.  
The negative association found between 25(OH)D and glucose serum levels is 
supported by several studies 513, 516. In fact, serum levels of 25(OH)D have been 
associated with a lower risk of type 2 diabetes 656.  VitD may have an effect on 
glycaemia by stimulating insulin secretion and decreasing IR. The presence of 
pancreatic 1-α-hydroxylase activity and consequent local production of 1,25(OH)2D, 
as well as the presence of VDRs in β-cell, allows the action of VitD in the modulation 
of β-cells calcium influx and insulin synthesis. IR may also decrease by VitD related 
increase of insulin receptor expression and insulin-induced glucose transport. 
The negative association found between triglycerides and 25(OH)D serum levels was 
previously reported 513, 516, 657. VitD may, by regulating the intracellular calcium 
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content of the adipocyte and the hepatocyte, influence the synthesis of triglycerides. 
Other possible mechanisms include inflammation and IR induced by hypovitaminosis 
D. 
The positive association found between physical exercise and 25 (OH) D serum levels 
may be explained by higher UV radiation exposure. In fact, this association was 
previously reported for regular outdoor physical activity 658. Nevertheless, the present 
study did not characterize the physical exercise in terms of indoor versus outdoor 
practice.  
Despite the reported association of PTH with CVD risk 526, no association was found 
between PTH serum levels and MetS. In fact the positive association with MetS was 
only described in older men 510, in morbidly obese 530 and primary 
hyperparathyroidism subjects 531, 532. However, a positive association was found 
between PTH serum levels and the WC component of MetS and PTH serum levels. 
This association of PTH with adipose indicators and with the WC components of MetS 
is in agreement with previous studies that support an effect of PTH on fat mass 651-653. 
As far as it is possible to know, however, this association with the WC component is 
not described in the literature, except in older men 510.  
Despite the reported association of PTH with systolic and diastolic BP 525, 531, 532, we 
did not find any association of PTH levels with BP values or with the BP component 
of MetS. Moreover, we did not find any association of PTH with other cardiometabolic 
risk factors or with their respective MetS components, namely with glycemia and low 
HDL cholesterol, previously reported 525. 
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Unlike PTH, serum levels of 25 (OH) D showed a negative association with MetS, 
losing its significance after adjustment for BMI.  
The association of low levels of 25(OH)D with MetS 502, 509 , 517 and CVD 479, 480, 494 is 
well documented. Furthermore, overall 659 and CVD 660 mortality may increase as 
levels of 25(OH)D decrease. Despite the reported association of hypovitaminosis D 
with CVD, it can not be ruled out that this associationis merely the result of obesity 
and associated IR 509. In fact, according to our data, the association is lost after 
adjustment for BMI. 
We found no association of the glucose and triglyceride components of MetS with the 
25(OH)D serum levels despite the above-mentioned negative linear associations for 
glucose and triglycerides serum levels, previously described 513, 516.  
In contrast, we found an association with the BP component of MetS although there 
was no linear association with diastolic or systolic BP. The negative association of 
VitD with hypertension 483, BP 510, 513, 516 and the BP component of MetS 171, 512, 514, 515 
has been previously reported and several mechanisms have been proposed to explain 
the association. Hypovitaminosis D may have a pressor effect through secondary 
hyperparathyroidism, a decrease in the inhibitory effect of renin gene expression, and 
an increase in vascular tonus by dysfunction of the endothelial and vascular smooth 
muscle cells. Finally, no association was found with WC and HDL cholesterol and its 
specific components of MetS. Although no association with WC was found, BMI was 
associated with serum levels of 25 (OHD). Regarding WC, several studies have shown 
an association of serum 25 (OH) D levels 171, 511, 512, 514, 515 with the WC component of 
MetS. The association found in these studies may be due to differences in the 
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characteristics of the samples studied, namely regarding the distribution by sex and 
age, prevalence of obesity, 25(OH)D serum levels distribution and ethnic specificities. 
The association with the HDL cholesterol component of MetS has been less reported 
171, 515, and several studies, in fact, reported no association at all 511, 512, 514. 
Thyroid dysfunction and autoimmunity have also been implicated in the 
etiopathogenesis of MetS, namely through mechanisms related to the action of thyroid 
hormones and chronic inflammation, respectively. 
In contrast to the malignant pathology 661, there is few available data on the prevalence 
of thyroid dysfunction and autoimmunity in Portugal. Only one study on the subject, 
involving pregnant and iodine-deficient women, was published 662. The prevalence of 
AIT (AATg and/or AATPO positivity) in this study was 10.7% and 8.0% of pregnant 
women without AIT, had subclinical hypothyroidism in the first trimester.  
The impact of thyroid dysfunction and autoimmune thyroiditis can also be assessed 
indirectly through consumption of health care. According to a report from the Sentinel 
Medical Network 663, approximately two thousand thyroid pathology medical 
appointments were performed by 100,000 National Health Service users during the 
year 2011; 4.9%, 34.0% and 6.2% of these medical appointments were related to 
hyperthyroidism, hypothyroidism and thyroiditis, respectively.  
According to our results, the prevalence of thyroid dysfunction (previously known and 
undiagnosed) was 7.4%, with a predominance of subclinical forms (63.9%). The 
prevalence of hypothyroidism and hyperthyroidism was 4.9% and 2.5%, respectively, 
with a higher prevalence of all forms of dysfunction in women. Comparing to other 
European studies 537, and with a United States study 664, we found a higher prevalence 
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of thyroid dysfunction. In addition, the prevalence of undiagnosed hypothyroidism and 
hyperthyroidism was, respectively, lower and higher compared to European findings 
537. 
The high prevalence of hyperthyroidism observed in our study may partially be 
explained by a borderline iodine intake 665, well-documented in Portuguese pregnant 
women and school populations 666-668. Although the structured questionnaire 
administered included questioning about drug treatment, responses were incomplete 
in many participants. Taking into account the additional information provided by the 
questionnaire on a prior diagnosis of hypothyroidism, it was possible to fill in any 
omissions on L-thyroxine treatment. Thus, interference of drugs, other than L-
thyroxine, with action on thyroid function cannot be excluded. 
According to our data, TPOAb and TgAb were positive in 11.9% (16.7% in women 
and 5.4% in men) and 15.1% (21.5% in women and 6.8% in men) of the participants, 
respectively. A high prevalence of thyroid antibody positivity was also found in 
participants without thyroid dysfunction. These results are similar to those of other 
European and USA studies. The estimated prevalence reported for TPOAb positivity 
in several European studies 669 ranged from 13.9% to 16.9% in women and between 
2.9% and 7.3% in men. In the NHANES III study, the prevalence of TPOAb and TgAb 
positivity was 13.0% (17% in women and 8.7% in men) and 11.5% (15.2% in women 
and 7.6% in men), respectively 664.  The prevalence of TgAb positivity was higher than 
for TPOAb. In other studies, the contrary was reported 664. Nevertheless, the 
comparison between epidemiological studies on the prevalence of thyroid antibodies 
can be hampered due to differences in epidemiological approaches, distribution by age 
  
Overall Discussion | 130 
 
and sex, as well as the ethnic characteristics and iodine intake of the studied 
populations 670. In addition to the absence of internationally standard assays, the 
available ones vary greatly in their cut-off points and their sensitivity and specificity 
to diagnose the positivity of thyroid antibodies. 
In a second step, several possible determinants of serum levels of TSH and thyroid 
hormones as well as positivity for thyroid antibodies were analysed.  
Unlike TSH and FT4, FT3 serum level had a negative association with age and gender 
(women). These associations were previously reported 554, 562, 671.  
Both thyroid antibodies presented a positive association with the female gender. 
However, we did not find an association with age, as reported in other studies 670. The 
higher prevalence of thyroid antibodies and autoimmune disorders in women 
compared to men is well documented 670, 672. This association has been mainly related 
to inflammatory mechanisms mediated by leptin and estrogens through the modulation 
of the immune response. Additionaly, miRNA expression differences between sexes 
have also been reported. Thyroid antibodies also showed a positive association with 
TSH levels, supporting the association of autoimmunity with hypothyroidism. 
The thyroid hormones have vast metabolic effects, influencing, in particular,  the lipid 
and glucose metabolism, the BP and body weight 545, 565 673. Regarding the association 
of TSH and thyroid hormones with the risk factors that integrate MetS, we only found 
a positive association of FT3 with triglyceride serum levels (p˂0.05). Previous studies 
have shown a significant positive association of FT3 levels with triglyceride levels 551, 
559, 564. We also found an association between FT3 and insulin serum levels. However, 
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no association was found with HOMA score, but the lack of sample power cannot be 
disregarded. The association of FT3 with IR was previously documented 551, 564.  
Finally, the associations of serum levels of TSH, thyroid hormones and thyroid 
antibodies positivity with MetS and its components were evaluated. No associations 
of TSH with MetS and its components were found in our study. Although the 
participants under treatment with thyroid hormone were excluded, our analysis 
included 29 participants with thyroid dysfunction. For this reason, comparisons with 
studies conducted in euthyroid populations may be difficult.  Although several studies 
conducted in euthyroid populations have documented the positive association of TSH 
with MetS others, on the contrary, did not find this association 547, 550, 554, 559, 560, 562. We 
also did not find an association between TSH and triglycerides levels 546, 552, 561 and its 
MetS component 553, 556, 558 as reported in some studies. Although only a minority of 
studies suggest a positive association of TSH with the glucose component 549, 562, a 
recent prospective study has shown an increased risk of type 2 diabetes in participants 
with low or low-normal thyroid function 543. Furthermore, as in other studies, we did 
not find a positive association with IR 552, 553, 555, 556, 561. Several cross-sectional studies 
674, 675 that evaluated the association between SCH and MetS have also found 
contradictory results. Two recent meta-analyses also failed to clarify this problem, 
albeit one of them found a positive association 674 whereas no association was found 
in the other 675. Furthermore, and although CVD risk and mortality may be increased 
in SCH 541, 542, namely among subjects younger than 65 years and in those with a TSH 
concentration greater than or equal to 10 mIU/L, normal TSH levels were not 
associated with an increase in CVD risk or mortality 676.  
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We also did not found an association of FT4 with MetS and its components. According 
to literature, the association of FT4 with MetS is poorly studied, with some studies 
suggesting a negative association 547, 548, 559, 562. However, these results were not 
replicated by other studies 554-556, 560, 563. In addition, and although some studies have 
suggested a negative association of FT4 levels with IR 547, 548, 552, we did not find in 
our study any association with HOMA score or insulin levels. Furthermore, the role of 
FT4 in CVD risk remains controversial 540. 
The FT3 serum levels presented a positive association with MetS. This association has 
been increasingly mentioned in the literature 551, 559, 560, 562, 677. We did not find any 
positive association with the BP, glucose, triglycerides and WC components of the 
MetS or a negative one with the HDL cholesterol component, as previously reported. 
Although no association was found with triglycerides component of MetS, levels of 
FT3 were positively associated with triglyceride levels as reported above. In addition, 
FT3 levels had a positive association with insulin levels. Several mechanisms have 
been proposed for the association of FT3 with MetS 551. Leptin produced by the 
adipocyte can stimulate the expression of the thyrotropin-releasing hormone gene 
directly in the paraventricular nucleus and indirectly in the arcuate nucleus, leading to 
hypothalamic-pituitary-thyroid axis stimulation. The adipose tissue may also be able 
to increase the conversion of T4 into T3 through the type 1 iodothyronine deiodinase 
activity. Furthermore, the increase in T3 levels may have a protective function in 
situations of increased adipose mass leading to increased caloric expenditure. In the 
fasting state, T3 levels are lower and in situations of overfeeding their levels increase. 
The proposed mechanisms suggest a role of fat mass and overfeeding in increasing 
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levels of FT3. Nevertheless, we found no association between FT3 levels and BMI or 
WC 
According to our results, TPOAb presented a negative association with MetS. Despite 
this, we did not find a negative association of TPOAb with HOMA score or with serum 
insulin levels. In addition, TPOAb also presented a negative association with the 
triglycerides component of the MetS. In addition, no associations were found for 
TgAb. The different behaviour of the two thyroid antibodies may eventually be 
explained on the basis of their immunological differences 539. Unlike TgAb, TPOAb 
may have a predictive value for the development of hypothyroidism 678. Data on a 
possible association of AIT with MetS is scarce and the limited evidence available 
does not favour an association, namely in obesity 679 and in postmenopausal women 
573. According to the literature, thyroid autoimmunity is not directly involved in MetS 
pathogenesis and no significant associations were previously reported between 
TPOAb and HOMA, glycaemia and insulin levels 680. The negative association of 
TPOAb positivity with the triglycerides component of the MetS is partially supported 
by a study that reported lower values of triglycerides in AIT and other autoimmune 
diseases 681. The mechanisms underlying this action on triglycerides are not yet fully 
understood but will likely not involve IR. 
In addition, no association was found of hs-CRP with thyroid antibodies, which is in 
agreement with the limited evidence available 682. Unlike other autoimmune diseases, 
the systemic inflammatory repercussions of autoimmune thyroid disease may be 
minor. Moreover, and according to literature 683, there was also no association of hs-
CRP with serum levels of TSH, FT4 or FT3. 
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An association has been already suggested of AIT with the risk of CVD 567-570 and 
inflammation has been proposed as a possible pathogenic mechanism 684-686. 
Nevertheless, TPOAb do not appear to be associated with CVD risk in SCH 687. 
Adding to that, the analysis of individual participant data from several studies 571 and 
a 20-year follow-up of the original Whickham survey 572 suggested that the CVD risk 
associated with autoimmunity is mediated by thyroid dysfunction. 
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VI. Conclusions 
 
Adiposity cut-off points for cardiovascular disease and diabetes risk in the 
Portuguese population: The PORMETS study. 
According to our data, WC, WHtR and BAI are the adiposity measures that provided 
the best evaluation of the adiposity component for MetS in the Portuguese population.  
Since WC is currently used as the adiposity measure in the definition of MetS and as 
no relevant differences were observed between this measure and the other adiposity 
measures evaluatedWHtR ratio, it is likely that no modification to the current MetS 
definition need to bewas proposed. 
The new WC cut-off points proposed for the Portuguese population (89.0 cm in 
females and 93.5 cm in males) are very similar to the “European” cut-off points in 
women and the “Europid” values in men.  
Use of the “European” cut-off points may be more appropriate in order to prevent over-
diagnosis in women. 
 
The prevalence of the metabolic syndrome in Portugal: the PORMETS study 
This study showed that MetS is highly prevalent in the Portuguese adult population. A 
high prevalence of hypertension, obesity and diabetes in Portugal, may contribute to 
these numbers. 
Ageing 398 and the trend towards increasing obesity in Portugal 96 are expected to 
contribute to a future increase in MetS prevalence.  
  
Conclusions | 136 
 
Differences in the prevalence of this syndrome were observed by district. Additionaly, 
this condition was more frequent in non-urban areas. These results may be useful in 
selecting priority sites for future national intervention. 
Our study provides valuable baseline information for the development of future 
interventions in Portugal and to assess the trends in the evolution of the MetS and 
associated risk factors. 
 
Vitamin D, parathyroid hormone and metabolic syndrome – the PORMETS 
study 
The present study showed a high prevalence of hypovitaminosis D in a sample of the 
Portuguese population. Compared with to other European and worldwide populations, 
our median level of 25(OH)D (13.8 ng/mL) is was considered relatively low. The 
prevalence of hypovitaminosis D was higher in participants with higher BMI and 
sedentary lifestyles.  
The PTH levels showed a significant positive association with BMI, WC and the WC 
component of MetS, suggesting a possible role in the pathophysiology of obesity. The 
25(OH)D levels were negatively associated with BMI, glucose and triglycerides levels 
as well as with MetS and its BP and triglycerides components, indicating that 
hypovitaminosis D may contribute to the pathophysiology of MetS. 
Considering the low levels and inadequate intake of VitD, the frequency of 
overweight, and potentially insufficient solar exposure in the Portuguese population, 
it is crucial to develop national policies to increase awareness of the importance of 
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VitD for health and to develop strategies for the identification of vitamin D deficiency, 
especially in at-risk groups. 
 
Metabolic Syndrome, Thyroid Function and Autoimmunity – the PORMETS 
Study. 
Our study showed a high prevalence of thyroid dysfunction. Moreover, the prevalence 
of subclinical and undiagnosed thyroid dysfunction was also high. 
Thyroid antibody positivity was high in our sample, namely in individuals with thyroid 
dysfunction. Even amongst participants with normal thyroid function, a high 
prevalence of thyroid antibody positivity was observed. 
In addition, no association was observed between TSH and FT4 and the MetS and its 
individual components. In contrast, FT3 levels presented a positive association with 
MetS, and insulin and triglycerides levels, strengthening the plausible role of this 
thyroid hormone in CVD risk.  
Finally, according to our data, thyroid autoimmunity did not contribute to an increase 
in the prevalence of MetS.was not associated with MetS prevalence. In fact, TPOAb 
levels presented an inverse association with MetS and its triglycerides component. 
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